

## Literatura ACTA MEDICINAE 10/2019 Onkologie

- 3 [Očekávání nového algoritmu léčby pokročilého karcinomu ledviny](#)  
prof. MUDr. Jindřich Fínek, Ph.D., MHA Onkologická a radioterapeutická klinika FN a LF UK, Plzeň
- 3 [Použití molekulárněgenetických metod v klinické onkologii](#)  
MUDr. Ludmila Křížová | prof. MUDr. Luboš Petruželka, CSc. Onkologická klinika VFN a ÚVN 1. LF UK, Praha
- 3 [Karcinom děložního hrdla, screening, význam HPV a možnosti testování](#)  
As. RNDr. Ing. Libor Staněk, PCTM synlab czech, s. r. o., ČR, Chirurgická klinika, 3. LF UK, Praha, Vysoká škola dravotníctva a sociálnej práce sv. Alžbety v Bratislavě  
prof. MUDr. František Mateička, CSc. Vysoká škola dravotníctva a sociálnej práce sv. Alžbety v Bratislavě
- 3 [Nová éra v adjuvantní léčbě pokročilého melanomu](#)  
MUDr. Ivana Krajsová, MBA Dermatovenerologická klinika VFN a 1. LF UK, Praha
- 4 [Výsledky multifaktoriální analýzy pětiletého sledování pacientů zařazených do studií COMBI-v a COMBI-d](#)  
MUDr. Eugen Kubala Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha
- 4 [Trastuzumab emtansin ve druhé linii HER2 metastatického karcinomu prsu: léčba, která není dostupná pro všechny potřebné pacienty](#)  
prof. MUDr. Petra Tesařová, CSc. Onkologická klinika 1. LF UK a Všeobecné fakultní nemocnice, Praha
- 4 [Současnost a výhledy v léčbě karcinomu prsu](#)  
MUDr. Markéta Palácová Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno
- 4 [Aktuální možnosti léčby karcinomu prsu](#)  
MUDr. Zuzana Bielčíková, Ph.D. Onkologická klinika 1. LF UK a VFN, Praha
- 5 [Vliv ribociclibu v kombinaci s endokrinní léčbou na celkové přežití u žen s karcinomem prsu – Studie MONALEESA-7](#)  
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha
- 5 [Nemetastatický kastročně rezistentní karcinom prostaty](#)  
MUDr. Jana Katolická, Ph.D. Onkologicko-chirurgické oddělení FN u sv. Anny v Brně
- 6 [Lorlatinib – zařazení do aktuální léčebné praxe](#)  
MUDr. Juraj Kultán Klinika plicních nemocí a tuberkulózy FN a LF UP v Olomouci
- 6 [Nový algoritmus léčby pokročilého NSCLC](#)  
doc. MUDr. Milada Zemanová, Ph.D. Onkologická klinika 1. LF UK a VFN, Praha
- 7 [Co nového v imunoterapii na WCLC 2019](#)  
MUDr. Leona Koubková Pneumologická klinika UK 2. LF a FN Motol, Praha
- 7 [Léčba kolorektálního karcinomu ve druhé linii](#)  
Rozhovor Mgr. Dany Frantálové s MUDr. Radmilou Lemstrovou, doc. MUDr. Tomášem Büchlerem, Ph.D., MUDr. Petrou Klimčíkovou, MUDr. Jiřím Tomáškem, Ph.D., MUDr. Stanislavem Johnem a MUDr. Zdeňkem Linkem
- 7 [Zkušenosti s bevacizumabem v první a druhé linii terapie pacientky s metastazujícím karcinomem rekta – kazuistika](#)  
MUDr. Michal Vočka Onkologická klinika, 1. LF UK a VFN, Praha
- 7 [Tromboembolické komplikace u onkologických pacientů a jejich primární profylaxe](#)  
prof. MUDr. Jan Kvasnička, DrSc. Trombotické centrum ÚLBLD a I. interní klinika VFN a 1. LF UK, Praha
- 8 [Léčebné konopí](#)  
MUDr. Marek Hák, Ph.D. Centrum léčby bolesti, Medicinecare, s. r. o., Chirurgická klinika FN a LF MU, Brno
- 8 [Možnosti léčby nádorové bolesti](#)  
MUDr. Jan Lejčko Centrum pro léčbu bolesti Anesteziologicko-resuscitační kliniky FN Plzeň
- 8 [Národní onkologické programy: klíč ke zlepšení onkologické péče – Annual Cancer Media Summit](#)

## Literatura ACTA MEDICINAE 11/2019 Hematoonkologie

- 8 **CAR-T lymfocyty v léčbě B-buněčných lymfomů**  
MUDr. Pavel Otáhal, Ph.D. | prof. MUDr. Marek Trněný, DrSc. I. interní klinika 1. LF a VFN, Praha
- 8 **Immune checkpoint inhibitory v léčbě Hodgkinova lymfomu**  
MUDr. Veronika Hanáčková | doc. MUDr. Vít Procházka, Ph.D. Hemato-onkologická klinika, FN Olomouc a LF UP, Olomouc
- 9 **Konjugované monoklonální protilátky v léčbě lymfomů**  
MUDr. Jan Kořen I. interní klinika – klinika hematologie, 1. LF UK a VFN, Praha
- 9 **Léčba nehodgkinských lymfomů monoklonálními protilátkami v roce 2019**  
MUDr. David Belada, Ph.D. IV. interní hematologická klinika, FN HK a LF UK v Hradci Králové
- 9 **Bispecifické protilátky v léčbě akutní lymfoblastové leukemie a lymfomů**  
MUDr. Kamila Polgárová | prof. MUDr. Marek Trněný, CSc. Interní klinika – klinika hematologie, 1. LF UK a VFN, Praha
- 10 **Lymfom z plášťových buněk ve světle nových poznatků**  
doc. MUDr. Pavel Klener, Ph.D. I. interní klinika hematologie, VFN a 1. LF UK, Praha
- 11 **Relabující lymfom z plášťových buněk léčený úspěšně ibrutinibem – kazuistika**  
MUDr. Juraj Ďuraš | prof. MUDr. Roman Hájek, CSc. Klinika hematoonkologie, FN Ostrava, Klinika hematoonkologie, LF Ostravské univerzity, Ostrava
- 11 **Ibrutinib v léčbě refrakterního lymfomu z plášťových buněk – kazuistika**  
MUDr. Heidi Móciková, Ph.D. Interní hematologická klinika FNKV a 3. LF UK, Praha
- 11 **Použití ibrutinibu jako „bridging“ k alogenní transplantaci krvetvorných buněk od haploidentického dárce a následné terapii reziduální nemoci po transplantaci u pacientky s vysoce nepříznivým průběhem lymfomu z plášťových buněk – kazuistika**  
MUDr. Veronika Válková, CSc. Ústav hematologie a krevní transfuze, Ústav klinické a experimentální terapie UK, Praha
- 11 **Cílená terapie chronické lymfocytární leukemie**  
MUDr. Jakub Trizuljak | prof. MUDr. Michael Doubek, Ph.D. Interní hematologická a onkologická klinika, Lékařská fakulta a Fakultní nemocnice Brno, Středoevropský technologický institut (CEITEC) Masarykovy univerzity, Brno
- 12 **Venetoklax – opakované použití u nemocné s prognosticky nepříznivou chronickou lymfocytární leukemií**  
MUDr. Jana Zuchnická Klinika hematoonkologie Fakultní nemocnice Ostrava
- 12 **Léčba esenciální trombocytémie anagrelidem**  
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha
- 13 **Buněčná terapie u akutních leukemií**  
MUDr. Jan Vydra Ústav hematologie a krevní transfuze, Praha
- 13 **Diagnostika a terapie sekundárních protilátkových imunodeficiencí u hematoonkologických pacientů z pohledu imunologa**  
MUDr. Tomáš Milota Ústav imunologie 2. LF UK a FN v Motole, Praha

# Očekávání nového algoritmu léčby pokročilého karcinomu ledviny

prof. MUDr. Jindřich Fínek, Ph.D., MHA Onkologická a radiotherapeutická klinika FN a LF UK, Plzeň

- 1 Motzer, J. R. – Tannir, N. M. – McDermott, D. F.: Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. *N Engl J Med*, 2018, 378, s. 1277–1290.
- 2 Motzer, R. J. – Tannir, N. M. – Dermott, D. F., et al.: Nivolumab plus ipilimumab versus sunitinib advanced renal-cell carcinoma. *NEJM*, 2018.
- 3 Choueiri, T. K. – Halabi, S. – Sanford, B. L., et al.: Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: The Alliance A031203 CA-BOSUN Trial. *J Clin Oncol*, 2017, 35, s. 591–597.
- 4 Rini, B. I. – Plimack, E. R. – Stus, V., et al.: Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. *N Engl J Med*, 2019, 380, s. 1116–1127.
- 5 Motzer, J. R. – Penkov, K. – Haanen, J., et al.: Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. *N Engl J Med*, 2019, 380, s. 1103–1115.
- 6 Motzer, R. J. – Powles, T. – Atkins, M. B., et al.: IMmotion 151: A randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC). *J Clin Oncol*, 2018, 36, s. 578–578.
- 7 www.sukl.cz

## Použití molekulárněgenetických metod v klinické onkologii

MUDr. Ludmila Křížová | prof. MUDr. Luboš Petruželka, CSc. Onkologická klinika VFN a ÚVN 1. LF UK, Praha

- 1 Petruželka, L.: Které nádory jsou skutečně vzácné? *Onkol Rev*, 2018, 4.
- 2 Sawyers, C.: Targeted cancer therapy. *Nature*, 2004, 432, s. 294–297.
- 3 Petruželka, L.: Pohled na vývoj onkologie ve 3. tisíciletí. *Klin Onkol*, 2009, 22, s. 243–244.
- 4 MacConaill, L. E. – Garraway, L. A.: Clinical implications of the cancer genome. *J Clin Oncol*, 2010, 28, s. 5219–5228.
- 5 Jameson, J. L. – Longo, D. L.: Precision medicine – personalized, problematic, and promising. *N Engl J Med*, 2015, 372, s. 2229–2234.
- 6 Hyman, D. M. – Taylor, B. S. – Baselga, J.: Implementing genome-driven oncology. *Cell*, 2017, 168, s. 584–599.
- 7 Kurzrock, R. – Giles, F. J.: Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes. *Cell Cycle*, 2015, 14, s. 2219–2221.
- 8 National Laboratory of Enteric Pathogens, Bureau of Microbiology, Laboratory Centre for Disease Control: The polymerase chain reaction: An overview and development of diagnostic PCR protocols at the LCDC. *Can J Infect Dis*, 1991, 2, s. 89–91.
- 9 Mullis, K. – Faloona, F. – Scharf, S., et al.: Specific enzymatic amplification of DNA in vitro: the polymerase chain reaction. 1986. *Biotechnology*, 1992, 24, s. 17–27.
- 10 Tichopad, A., et al.: Standardized determination of real-time PCR efficiency from a single reaction set-up. *Nucleic Acids Res*, 2003, 31, s. e122.
- 11 Banda, M.: Detection of mutant RAS subpopulations in colorectal cancer patients. *E Bio Medicine*, 2015, 2, s. 280–281.
- 12 Jader, J. N. – Sharif, S. B. – Shakhinia, E.: Microsatellite instability in colorectal cancer. *EXCLI J*, 2018, 17, s. 159–168.
- 13 Wolff, D. J.: Fluorescence in situ hybridization (FISH). In: *The Principles of Clinical Cytogenetics*, 2013, s. 415–439.
- 14 Arbour, K. C. – Riley, G. J.: Diagnosis and treatment of ALK positive NSCLC. *Hematol Oncol Clin North Am*, 2017, 31, s. 101–111.
- 15 Gutierrez, C. – Schiff, R.: HER2: Biology, detection, and clinical implications. *Arch Pathol Lab Med*, 2011, 135, s. 55–62.
- 16 Albarello, L. – Pecciarini, L. – Doglioni, C.: HER2 testing in gastric cancer. *Adv Anat Pathol*, 2011, 18, s. 53–59.
- 17 Aitman, T. J.: Science, medicine, and the future: DNA microarrays in medical practice. *BMJ*, 2001, 323, s. 611–615.
- 18 Bernard, P. S. – Wittwer, C. T.: Real-time PCR technology for cancer diagnostics. *Clin Chem*, 2002, 48, s. 1178–1185.
- 19 Chen, C. Y.: DNA polymerase driven DNA sequencing-by-synthesis technologies: Both past and present. *Front Microbiol*, 2014, 5, s. 305.
- 20 Bennett, S. T. – Barnes, C. – Cox, A., et al.: Toward the 1,000 dollars human genome. *Pharmacogenomics*, 2005, 6, s. 373–382.
- 21 Rizzo, J. M. – Buck, M. J.: Key principles and clinical applications of “next-generation” DNA sequencing. *Cancer Prev Res*, 2012, 5, s. 887–900.
- 22 Kamps, R. – Brandão, R. – Bosch, B., et al.: Next-generation sequencing in oncology: genetic diagnosis, risk prediction and cancer classification. *Int J Mol Sci*, 2017, 18, s. pii: E308.
- 23 Mark, J. R. – Kucherov, V. – Pintaura, M., et al.: What is the clinical utility of next generation sequencing (NGS) in advanced urologic malignancies? *J Clin Oncol*, 2019, 37, suppl., s. 285–285.
- 24 Soukupová, J. – Zemánková, P. – Kleiblová, P., et al.: CZECHANCA: CZEch Cancer panel for Clinical Application – design and optimization of the targeted sequencing panel for the identification of cancer susceptibility in high-risk individuals from the Czech Republic. *Klin Onkol*, 2016, 29, suppl. 1, s. S46–S54.
- 25 Neumann, M. H. D. – Bender, S. – Krahn, T., et al.: ctDNA and CTCs in liquid biopsy – current status and where we need to progress. *Comput Struct Biotechnol J*, 2018, 16, s. 190–195.
- 26 Moorcraft, S. Y. – Gonzalez, D. – Walker, B. A.: Understanding next generation sequencing in oncology: A guide for oncologists. *Crit Rev Oncol Hematol*, 2015, 96, s. 463–474.
- 27 Stricker, T. – Catenacci, D. V. T. – Seiwert, T. Y.: Molecular profiling of cancer – the future of personalized cancer medicine: A primer on cancer biology and the tools necessary to bring molecular testing to the clinic. *Semin Oncol*, 2011, 38, s. 173–185.
- 28 Subbiah, V. – Kurzrock, R.: Universal genomic testing needed to win the war against cancer: Genomics IS the diagnosis. *JAMA Oncol*, 2016, 2, s. 719–720.
- 29 Wheler, J. – Lee, J. J. – Kurzrock, R.: Unique molecular landscapes in cancer: Implications for individualized, curated drug combinations. *Cancer Res*, 2014, 74, s. 7181–7184.
- 30 Slabý, O.: Technologie sekvenování nové generace: celogenomové, celoxomové a cílené – hotspot – sekvenování 2018. [www.prolekare.cz](http://www.prolekare.cz)
- 31 Shyr, D. – Liu, Q.: Next generation sequencing in cancer research and clinical application. *Biol Proced Online*, 2013, 15, s. 4.

## Karcinom děložního hrdla, screening, význam HPV a možnosti testování

As. RNDr. Ing. Libor Staněk, PCTM synlab czech, s. r. o., ČR, Chirurgická klinika, 3. LF UK, Praha, Vysoká škola dravotnictva a sociálnej práce sv. Alžbety v Bratislavě

prof. MUDr. František Matejíčka, CSc. Vysoká škola dravotnictva a sociálnej práce sv. Alžbety v Bratislavě

- 1 Dušek, L. – Mužík, J. – Kubásek, M., et al.: Epidemiologie zhoubných nádorů v České republice [online]. Masarykova univerzita, [2005], [cit. 2014–8-10]. Dostupný z WWW: <http://www.svod.cz>. Verze 7.0 [2007].
- 2 De Sanjose, S. – Quint, W. G. – Alemany, L., et al.: Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. *Lancet Oncol*, 2010, 11, s. 1048–1056.
- 3 Tachezy, R. – Mahelova, J. – Salačova, M., et al.: Human papillomavirus genotype distribution in Czech women and men with diseases etiologically linked to HPV. *PLoS One*, 2011, 6, s. 21913.
- 4 Cibula, D. – Petruželka, L., et al.: *Onkogynéologie*. Grada Publishing, Praha, 2009, s. 616.
- 5 Dundr, P. – Němejcová, B.: *Prekancerózy a karcinomy děložního hrdla. Doporučený postup pro biopické vyšetření*. Společnost českých patológů, [www.patologie.info](http://www.patologie.info).
- 6 McCluggage, W. G.: New developments in endocervical glandular lesions. *Histopathology*, 2013, 1, s. 138–160.
- 7 Robová, H. – Rob, L. – Pluta, M., et al.: *Guideline gynekologických zhoubných nádorů: Standard – komplexní léčba časných stadií zhoubných nádorů děložního hrdla*. Guideline C53 2013, [www.onkogynéologie.com](http://www.onkogynéologie.com).
- 8 Sangrajrang, S. – Laowahutanont, P. – Wongsena, M., et al.: Human papillomavirus (HPV) DNA and mRNA primary cervical cancer screening: Evaluation and triaging options for HPV-positive women. *J Med Screen*, 31. 7. 2019.
- 9 Vink, F. J. – Meijer, C. J. L. M. – Clifford, G. M., et al.: FAM19A4/miR124-2 methylation in invasive cervical cancer: A retrospective cross-sectional worldwide study. *Int J Cancer*, 7. 8. 2019.

## Nová éra v adjuvantní léčbě pokročilého melanomu

MUDr. Ivana Krajsová, MBA Dermatovenerologická klinika VFN a 1. LF UK, Praha

- 1 National Cancer Institute. Surveillance, epidemiology and end results (SEER). 12/2018.
- 2 Leiter, U. – Stadler, R. – Mauch, C., et al.: Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT). *Lancet Oncol*, 2016, 17, s. 757–767.
- 3 Faries, M. B. – Thompson, J. F. – Cochran, A. J., et al.: Completion dissection or observation for sentinel node metastasis in melanoma. *N Engl J Med*, 2017, 376, s. 2211–2222.
- 4 Ives, N. J. – Suciú, S. – Eggermont, A. M. M., et al.: International melanoma meta-analysis collaborative group (IMMCG). Adjuvant interferon alpha for the treatment of high risk melanoma: an individual patient data meta-analysis. *Eur J Cancer*, 2017, 82, s. 171–183.
- 5 Eggermont, A. M. – Chiarion-Sileni, V. – Grob, J. J., et al.: Adjuvant ipilimumab versus placebo after complete resection of high risk stage III melanoma (EORTC 18071): a randomised, double blind, phase 3 trial. *Lancet Oncol*, 2015, 16, s. 522–530.
- 6 Eggermont, A. M. – Chiarion-Sileni, V. – Grob, J. J., et al.: Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. *N Engl J Med*, 2016, 375, s. 1845–1855.
- 7 Tarhini, A. A. – Lee, J. S. – Hodi, S., et al.: United states Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3or 10 mg/kg) versus high-dose interferon alfa 2b for resected high-risk melanoma. *J Clin Oncol*, 2019, 37, suppl., abstrakt 9515.
- 8 Weber, J. – Mandala, M. – Del Vecchio, H. J., et al.: Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. *N Engl J Med*, 2017, 377, s. 1824–1835.
- 9 Eggermont, A. M. M. – Blank, C. U. – Mandala, M., et al.: Adjuvant pembrolizumab versus placebo in resected stage III melanoma. *N Engl J Med*, 2018, 378, s. 1789–1801.
- 10 Long, G. V. – Hauschild, A. – Santinami, M., et al.: Adjuvant dabrafenib plus trametinib in stage III BRAF mutated melanoma. *N Engl J Med*, 2017, 377, s. 1813–1823.
- 11 Hauschild, A. – Dummer, R. – Schadendorf, D., et al.: Longer follow-up confirms relaps free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600 mutant stage III melanoma. *J Clin Oncol*, 2018, 36, s. 3441–3449.
- 12 Schadendorf, D. – Hauschild, A. – Santinami, M., et al.: Effect on health-related quality of life (HRQL) of adjuvant treatment with dabrafenib plus trametinib in patients with resected stage III BRAF mutant melanoma. *J Clin Oncol*, 2018, 36, suppl., abstrakt 9590.

# Výsledky multifaktoriální analýzy pětiletého sledování pacientů zařazených do studií COMBI-v a COMBI-d

MUDr. Eugen Kubala Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha

- Haluska, F. G. – Tsao, H. – Wu, H., et al.: Genetic alteration in signaling pathways in melanoma. *Clin Cancer Res*, 2006, 12, s. 2301–2307.
- Menzies, A. M. – Haydu, L. E. – Visintin, L., et al.: Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. *Clin Cancer Res*, 2012, 18, s. 3242–3249.
- Long, G. V. – Menzies, A. M. – Nagrial, A. M., et al.: Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. *J Clin Oncol*, 2011, 29, s. 1239–1246.
- Chapman, P. B. – Hauschild, A. – Robert, C., et al.: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. *N Engl J Med*, 2011, 364, s. 2507–2516.
- Hauschild, A. – Grob, J. J. – Demidov, L. V., et al.: Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. *Lancet*, 2012, 380, s. 358–365.
- Robert, C. – Karaszewska, B. – Schachter, J., et al.: Improved overall survival in melanoma with combined dabrafenib and trametinib. *N Engl J Med*, 2015, 372, s. 30–39.
- Long, G. V. – Stroyakovskiy, D. K. – Gogas, H., et al.: COMBI-d: a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma. *J Clin Oncol*, 2015, 33, suppl., abstrakt 102.
- Robert, C. – Grob, J. J. – Stroyakovskiy, D., et al.: Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. *N Engl J Med*, 2019, 381, s. 626–636.
- Long, G. V. – Grob, J. J. – Nathan, P., et al.: Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. *Lancet Oncol*, 2016, 17, s. 1743–1754.
- Hamid, O. – Robert, C. – Daud, A., et al.: 5-Year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001. *J Clin Oncol*, 2018, 36, s. 9516, abstrakt.
- Hodi, F. S. – Kluger, H. – Sznol, M., et al.: Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial. *Proc Am Assoc Cancer Res*, 2016, 76, suppl., CT001, abstrakt.
- Robert, C. – Schachter, J. – Long, G. V., et al.: 5-Year survival and other long-term outcomes from KEYNOTE-006 study of pembrolizumab (pembro) for ipilimumab (ipi)-naïve advanced melanoma. Presented at the American Association for Cancer Research Annual Meeting, Atlanta, 29. 3.–3. 4. 2019, abstrakt.
- Prieto, P. A. – Yang, J. C. – Sherry, R. M., et al.: CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. *Clin Cancer Res*, 2012, 18, s. 2039–2047.
- Maio, M. – Grob, J. J. – Aamdal, S., et al.: Five year survival rates for treatment-naïve patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. *J Clin Oncol*, 2015, 33, s. 1191–1196.
- Ugurel, S. – Rohmel, J. – Paolo, A., et al.: Survival of patients with advanced metastatic melanoma: the impact of novel therapies update 2017. *Eur J Cancer*, 2017, 83, s. 247–257.
- Long, G. V. – Weber, J. S. – Infante, J. R., et al.: Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib. *J Clin Oncol*, 2016, 34, s. 871–878.
- Weide, B. – Martens, A. – Hassel, J. C., et al.: Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. *Clin Cancer Res*, 2016, 55, s. 5487–5496.

## Trastuzumab emtansin ve druhé linii HER2 metastatického karcinomu prsu: léčba, která není dostupná pro všechny potřebné pacienty

prof. MUDr. Petra Tesařová, CSc. Onkologická klinika 1. LF UK a Všeobecné fakultní nemocnice, Praha

- Teicher, B. A. – Doroshow, J. H.: The promise of antibody-drug conjugates. *N Engl J Med*, 2012, 367, s. 1847–1848.
- Verma, S. – Miles, D. – Gianni, L., et al.: Trastuzumab emtansine for HER2-positive advanced breast cancer. *N Engl J Med*, 2012, 367, s. 1783–1791.

## Současnost a výhledy v léčbě karcinomu prsu

MUDr. Markéta Palácová Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno

- Liedtke, C. – Mazouni, C. – Hess, K. R., et al.: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. *J Clin Oncol*, 2008, 26, s. 1275–1281.
- Osborne, C. R. – Kannan, L. – Xie, X. J., et al.: Neoadjuvant chemotherapy for basal-like breast cancer cohort: clinical and pathological outcomes. *Breast Cancer Res and Treat*, 2006, 100, s. 553.
- Dent, R. – Trudeau, M. – Pritchard, K. I., et al.: Triple-negative breast cancer: clinical features and patterns of recurrence. *Clin Cancer Res*, 2007, 13, s. 4429–4434.
- Carey, L. A. – Dees, E. C. – Sawyer, L., et al.: The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. *Clin Cancer Res*, 2007, 13, s. 2329–2334.
- Haffy, B. G. – Yang, Q. – Reiss, M., et al.: Locoregional relaps and distant metastasis in conservatively managed triple negative early-stage breast cancer. *J Clin Oncol*, 2006, 24, s. 5652–5657.
- Cortazar, P. – Zhang, L. – Untch, M., et al.: Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. *Lancet*, 2014, 384, s. 164–172.
- von Minckwitz, G. – Untch, M. – Blohmer, J. U., et al.: Definition and impact of pathological complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. *J Clin Oncol*, 2012, 30, s. 1796–1804.
- Harbeck, N. – Gluz, O.: Neoadjuvant therapy for triple negative and HER-2 positive early breast cancer. *Breast*, 2017, 34, s. S99–S103.
- Denkert, C. – von Minckwitz, G. – Darb-Esfahani, S., et al.: Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. *Lancet Oncol*, 2018, 19, s. 40–50.
- Loi, S. – Drubay, D. – Adams, S., et al.: Tumour-infiltrating lymphocytes and prognosis: A pooled individual patient analysis of early-stage triple-negative breast cancers. *J Clin Oncol*, 2019, 37, s. 559–570.
- Schmid, P. – Adams, S. – Rugo, H. D., et al.: Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. *N Engl J Med*, 2018, 29, 379, s. 2108–2121.
- Tolaney, S. M. – Guo, H. – Pernas, S., et al.: Seven-year follow-up of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2 – positive breast cancer. *J Clin Oncol*, 2019, 37, s. 1868–1875.
- Guarneri, V. – Dieci, M. V. – Bisagni, G., et al.: De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2 weeks letrozole: results of the PerELISA neoadjuvant study. *An Oncol*, 2019, 30, s. 921–926.
- Rimawi, M. F. – De Angelis, C. – Contreras, A., et al.: Low PTEN levels and PIK3CA mutation predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. *Breast Cancer Res Treat*, 2018, 167, s. 731–740.
- Pivot, X. – Romieu, G. – Debléd, M., et al.: 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomized phase 3 trial. *Lancet Oncol*, 2013, 14, s. 741–748.
- Earl, H. M. – Hiller, L. – Vallier, A. L., et al.: 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. *Lancet*, 2019, 393, s. 2599–2612.
- Conte, P. – Frassoldati, A. – Bisagni, G., et al.: Nine keks versus one aer adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. *An Oncol*, 2018, 29, s. 2328–2333.
- Von Minckwitz, G. – Huang, C. S. – Mano, M. S., et al.: Trastuzumab emtansine for residual invasive HER2-positive breast cancer. *N Engl J Med*, 2019, 380, s. 617–628.
- McCart Reed, A. E. – Kalita-deCroft, P. – Kutasovic, J. R., et al.: Recent advances in breast cancer research impacting clinical diagnostic practice. *J Pathol*, 2019, 247, s. 552–562.
- Davies, C. – Godwin, J. – Gray, R., et al.: Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomized trials. *Lancet*, 2011, 378, s. 771–784.
- Schiavon, G. – Smith, I. E.: Status of adjuvant endocrine therapy for breast cancer. *Breast Cancer Res*, 2014, 16, s. 206.
- Turner, N. C. – Ro, J. – Andre, F., et al.: Palbociclib in hormone-receptor-positive advanced breast cancer. *N Engl J Med*, 2015, 373, s. 209–219.
- Cristofanilli, M. – Turner, C. N. – Bondarenko, I., et al.: Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor positive, HER2-negative metastatic breast cancer, that progressed on previous endocrine therapy (PALOMA-3): final analysis of multicentre, double-blind, phase 3 randomised controlled trial. *Lancet Oncol*, 2016, 17, s. 425–439.
- Turner, N. C. – Slamon, D. J. – Jungslil, R., et al.: Overall survival with palbociclib and fulvestrant in advanced breast cancer. *N Engl J Med*, 2018, 379, s. 1926–1936.
- Hortobagyi, G. N. – Stemmer, S. M. – Burris, H. A., et al.: Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus letrozole alone in hormone receptor-positive, HER2-negative advanced breast cancer. *Ann Oncol*, 2018, 29, s. 1541–1547.
- Slamon, D. J. – Neven, P. – Chia, S., et al.: Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, HER2-negative advanced breast cancer: MONALEESA-3. *J Clin Oncol*, 2018, 36, s. 2465–2472.
- Goetz, M. P. – Toi, M. – Campono, M., et al.: MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. *J Clin Oncol*, 2017, 35, s. 3638–3646.
- Sledge, G. W. Jr. – Toi, M. – Neven, P., et al.: MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR1/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. *J Clin Oncol*, 2017, 25, s. 2875–2884.
- André, F. – Ciruelos, E. – Rubovszky, G., et al.: Alpelisib for PIK-3CA-mutated, hormone receptor-positive advanced breast cancer. *N Engl J Med*, 2019, 380, s. 1929–1940.

## Aktuální možnosti léčby karcinomu prsu

MUDr. Zuzana Bielčíková, Ph.D. Onkologická klinika 1. LF UK a VFN, Praha

- EBCTCG. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. *Lancet*, 2019, 393, s. 1440–1452.
- Masudan, N. – Lee, S. J. – Ohtani, S., et al.: Adjuvant capecitabine for breast cancer after preoperative chemotherapy. *NEJM*, 2017, 376,

- s. 2147–2159.
- Blum, J. L. – Flynn, P. J. – Yothers, G., et al.: Anthracyclines in early breast cancer: the ABC trials—USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). *J Clin Oncol*, 2017, 35, s. 2647–2655.
  - Ejlertsen, B. – Tuxen, M. K. – Jakobsen, E. H., et al.: Adjuvant cyclophosphamide and docetaxel with or without epirubicin for early T0-P2A-normal breast cancer: DBCG 07-READ, an open-label, phase iii, randomized trial. *J Clin Oncol*, 2017, 35, s. 2639–2646.
  - Gluz, O. – Nitz, U. – Christgen, M., et al.: Five-year results of the prospective Phase III WSG PlanB trial confirm prognostic impact of 21-Gene Recurrence Score in high-risk HR+/HER2– early breast cancer (EBC) patients with 1–3 involved lymph nodes. *The Breast*, 2017, 32, s. 93.
  - Gray, R., et al.: Extended aromatase inhibitor treatment following 5 or more years of endocrine therapy: A meta-analysis of 22,192 women in 11 randomized trials. *SABCS*, 2018, abstract G, s. 2–4.
  - Prudence A. F. – Pagani, O. – Fleming, G. F., et al.: Tailoring adjuvant endocrine therapy for premenopausal breast cancer. *NEJM*, 2018, 379, s. 122–137.
  - Sparano, J. A. – Gray, R. J. – Makower, D. F., et al.: Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. *NEJM*, 2018, 379, s. 111–121.
  - Cardoso, F. – van't Veer, L. J. – Bogaerts, J., et al.: 70-gene signature as an aid to treatment decisions in early-stage breast cancer. *NEJM*, 2016, 375, s. 717–729.
  - Gianni, L. – Pienkowski, T. – Im, Y. H., et al.: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. *Lancet Oncol*, 2012, 13, s. 25–32.
  - Schneeweiss, A. – Chia, S. – Hickish, T., et al.: Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). *Ann Oncol*, 2013, 24, s. 2278–2284.
  - von Minckwitz, G. – Procter, M. – De Azambuja, E., et al.: Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. *NEJM*, 2017, 377, s. 122–131.
  - Martin, M. – Holmes, F. A. – Ejlertsen, B., et al.: Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*, 2017, 8, s. 1688–1700.
  - Von Minckwitz, G. – Huang, Ch. S. – Mano, M. S., et al.: Trastuzumab emtansine for residual invasive HER2-positive breast cancer. *NEJM*, 2019, 380, s. 617–628.
  - Tolaney, S. M. – Barry, W. T. – Guo, H., et al.: Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC). *J Clin Oncol*, 2017, 35, s. 511.
  - Inno, A. – Barni, S. – Ghidini, A., et al.: One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis. *Breast Cancer Res Treat*, 2019, 173, s. 247–254.
  - Ruhstaller, T. – Giobbie-Hurder, A. – Colleoni, M., et al.: Adjuvant letrozole and tamoxifen alone or sequentially for postmenopausal women with hormone receptor-positive breast cancer: long-term follow-up of the BIG 1-98 Trial. *J Clin Oncol*, 2019, 2, s. 105–114.
  - Cardoso, F. – Costa, A. – Senkus, E., et al.: 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). *Breast*, 2017, 31, s. 244–259.
  - Finn, R. S. – Crown, J. P. – Lang, I., et al.: The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. *Lancet Oncol*, 2015, 16, s. 25–35.
  - Finn, R. S. – Martin, M. – Rugo, H. S., et al.: Palbociclib and letrozole in advanced breast cancer. *NEJM*, 2016, 375, s. 1925–1936.
  - Hortobagyi, G. N. – Stemmer, S. M. – Burris, H. A., et al.: Ribociclib as first-line therapy for HR-positive, advanced breast cancer. *NEJM*, 2016, 375, s. 1738–1748.
  - Goetz, M. P. – Toi, M. – Campone, M., et al.: MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. *J Clin Oncol*, 2017, 35, s. 3638–3646.
  - Slamon, D. J. – Neven, P. – Chia, S., et al.: Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. *J Clin Oncol*, 2018, 36, s. 2465–2472.
  - Tripathy, D. – Im, S. A. – Colleoni, M., et al.: Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): A randomized phase 3 trial. *Lancet Oncol*, 2018, 19, s. 904–915.
  - Im, S. A. – Lu, Y. S. – Bardia, A., et al.: Overall survival with ribociclib plus endocrine therapy in breast cancer. *NEJM*, 2019, 381, s. 307–316.
  - Neven, P. – Rugo, H. S. – Tolaney, S. M., et al.: Abemaciclib for pre/perimenopausal women with HR+/HER2– advanced breast cancer. *J Clin Oncol*, 2018, 36, abstrakt 1002.
  - Loibl, S. – Rurner, N. C. – Ro, J., et al.: Palbociclib combined with fulvestrant in premenopausal women with advanced breast cancer and prior progression on endocrine therapy: PALOMA-3 results. *Oncologist*, 2017, 22, s. 1028–1038.
  - Robertson, J. F. – Bondarenko, I. M. – Trishina, E., et al.: Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. *Lancet Oncol*, 2016, 388, s. 2997–3005.
  - Metha, R. S. – Barlow, W. E. – Albain, K. S., et al.: Combination anastrozole and fulvestrant in metastatic breast cancer. *NEJM*, 2012, 367, s. 435–444.
  - Ellis, M. J. – Llombart-Cussak, A. – Feltl, D., et al.: Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II FIRST Study. *J Clin Oncol*, 2015, 32, s. 3781–3787.
  - Baselga, J. – Campone, M. – Piccart, M., et al.: Everolimus in postmenopausal hormone receptor-positive advanced breast cancer. *NEJM*, 2012, 366, s. 520–529.
  - Andre, F. – Ciruelos, E. M. – Rubovszky, G., et al.: LBA3\_PR: Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial. *Ann Oncol*, 2018, abstr. LBA3.
  - Sledge, G. W. – Toi, M. – Neven, P., et al.: MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2– advanced breast cancer who had progressed while receiving endocrine therapy. *J Clin Oncol*, 2017, 35, s. 2875–2884.
  - Cristofanelli, M. – Turner, N. C. – Bondarenko, I., et al.: Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. *Lancet Oncol*, 2016, 17, s. 425–439.
  - Dickler, M. – Tolaney, S. M. – Rugo, H. S., et al.: MONARCH-1: results from a phase 2 study of abemaciclib, CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2– breast cancer, after chemotherapy for metastatic disease. *J Clin Oncol*, 2016, 34, abstrakt 510.
  - Barroso Sousa, R. – Shapiro, G. I. – Tolaney, S. M.: Clinical development of the CDK4/6 inhibitors ribociclib and abemaciclib in breast cancer. *Breast Care (Basel)*, 2016, 11, s. 167–173.
  - Varella, L. – Abraham, J. – Kruse, M., et al.: Revisiting the role of bevacizumab in the treatment of breast cancer. *Semin Oncol*, 2017, 44, s. 273–285.
  - Schmid, P. – Adams, S. – Rugo, H. S., et al.: Results from a global, randomised, double-blind, phase 3 study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naïve, locally advanced or metastatic triple-negative breast cancer (mTNBC). *Ann Oncol*, 2018, 29, abstrakt LBA1\_PR.
  - Loi, S. – Drubay, D. – Adams, S., et al.: Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. *J Clin Oncol*, 2019, 37, s. 559–569.
  - Robson, M. E. – Im, S. – Senkus, E., et al.: Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. *NEJM*, 2017, 377, s. 523–533.
  - Robson, M. E. – Tung, N. – Conte, P., et al.: OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. *Ann Oncol*, 2019, 30, s. 558–566.
  - Slamon, D. J. – Leyland-Jones, B. – Shak, S., et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *NEJM*, 2001, 344, s. 783–792.
  - Gelman, K. – Boyle, F. – Kaufman, B., et al.: Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919. *J Clin Oncol*, 2012, 30, abstrakt LBA671.
  - Hurvitz, S. A. – Andre, F. – Jiang, Z., et al.: Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. *Lancet Oncol*, 2015, 6, s. 816–829.
  - Baselga, J. – Cortez, J. – Kim, S. B., et al.: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. *NEJM*, 2012, 366, s. 109–119.
  - Swain, S. M. – Baselga, J. – Kim, S. B., et al.: Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. *NEJM*, 2015, 372, s. 724–734.
  - Romond, E. H. – Perey, E. A. – Brzant, J., et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. *NEJM*, 2005, 353, s. 1673–1684.
  - Verma, S. – Miles, D. – Gianni, L., et al.: Trastuzumab emtansine for HER2-positive advanced breast cancer. *NEJM*, 2012, 367, s. 1783–1791.
  - Andre, F. – O'Regan, R. – Ozguroglu, M., et al.: Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind. *Lancet Oncol*, 2014, 15, s. 580–591.
  - Harbeck, N. – Huang, C. H. S. – Hurvitz, S., et al.: Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. *Lancet Oncol*, 2016, 17, s. 357–366.
  - Krop, I. E. – Kim, S. B. – González-Martín, A., et al.: Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. *Lancet Oncol*, 2014, 15, s. 689–699.
  - Blackwell, K. L. – Burstein, H. J. – Storniolo, A. M., et al.: Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. *J Clin Oncol*, 2010, 28, s. 1124–1130.
  - Sella, T.: 8th Annual Fellows Forum in Breast Oncology 2019, přednáška.
  - Marra, A.: 8th Annual Fellows Forum in Breast Oncology 2019, přednáška.

## Vliv ribociclibu v kombinaci s endokrinní léčbou na celkové přežití u žen s karcinomem prsu – Studie MONALEESA-7

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha

- Caldon, C. E. – Daly, R. J. – Sutherland, R. L. – Musgrove, E. A.: Cell cycle control in breast cancer cells. *J Cell Biochem*, 2006, 97, s. 261–274.
- Koboldt, D. C. – Fulton, R. S. – McLellan, M. D., et al.: Comprehensive molecular portraits of human breast tumours. *Nature*, 2012, 490, s. 61–70.
- Zardavas, D. – Baselga, J. – Piccart, M.: Emerging targeted agents in metastatic breast cancer. *Nat Rev Clin Oncol*, 2013, 10, s. 191–210.
- Im, S. A. – Lu, Y. S. – Bardia, A., et al.: Overall survival with ribociclib plus endocrine therapy in breast cancer. *N Engl J Med*, 2019, doi: 10.1056/NEJMoa1903765, ePub před tiskem.

## Nemetastatický kastročně rezistentní karcinom prostaty

MUDr. Jana Katolická, Ph.D. Onkologicko-chirurgické oddělení FN u sv. Anny v Brně

- Freedland, S. J. – Richhariya, A. – Wang, H., et al.: Treatment patterns in patients with prostate cancer and bone metastasis among US community-based urology group practices. *Urology*, 2012, 80, s. 293–298.
- Esther, J. – Maughan, B. J. – Anderson, N., et al.: Management of nonmetastatic castration-resistant prostate cancer: recent advances and future direction. *Curr Treat Options in Oncol*, 2019, 20, s. 14.
- Smith, M. R. – Saad, F. – Chowdhury, S., et al.: Apalutamide treatment and metastasis-free survival in prostate cancer. *N Engl J Med*, 2018, 378, s. 1408–1418.
- Hussain, M. – Fizazi, K. – Saad, F., et al.: Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. *N Engl J Med*, 2018, 378, s. 2465–2474.
- Fizazi, K. – Shore, N. – Tammela, T. L., et al.: Darolutamide in nonmetastatic, castration-resistant prostate cancer. *N Engl J Med*, 2019, DOI: 10.1056/NEJMoa1815671.

- 6 Beaver, J. A. – Kluetz, P. G. – Pazdur, R.: Metastasis-free survival: a new end point in prostate cancer trials. *N Engl J Med*, 2018, 378, s. 2458–2460.
- 7 Afshar, M. – Evison, F. – James, N. D., et al.: Shifting paradigms in the estimation of survival for castration resistant prostate cancer: a tertiary academic center experience. *Urol Oncol*, 2015, 33, s. 338.e1–7.
- 8 Smith, M. R. M. – Nair, S. – Lawson, J., et al.: Association of metastasis-free survival (MFS) and overall survival (OS) in nonmetastatic

castration-resistant prostate cancer (nmCRPC). *J Clin Oncol*, 2018, 36, abstrakt 5032.

## Lorlatinib – zařazení do aktuální léčebné praxe

MUDr. Juraj Kultán klinika plicních nemocí a tuberkulózy FN a LF UP v Olomouci

- 1 Robinson, D. R. – Wu, Y. M. – Lin, S. F.: The protein tyrosine kinase family of the human genome. *Oncogene*, 2000, 19, s. 5548–5557.
- 2 Hubbard, S. R. – Miller, W. T.: Receptor tyrosine kinases: mechanisms of activation and signaling. *Curr Opin Cell Biol*, 2007, 19, s. 117–123.
- 3 Sanz-Ezquerro, J. J. – Münsterberg, A. E. – Stricker, S.: Editorial: signaling pathways in embryonic development. *Front Cell Dev Biol*, 2017, 5, s. 76.
- 4 Bayliss, R. – Choi, J. – Fennell, D. A., et al.: Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs. *Cell Mol Life Sci*, 2016, 73, s. 1209–1224.
- 5 Mathas, S. – Kreher, S. – Meaburn, K. J., et al.: Gene deregulation and spatial genome reorganization near breakpoints prior to formation of translocations in anaplastic large cell lymphoma. *Proc Natl Acad Sci U S A*, 2009, 106, s. 5831–5836.
- 6 Du, X. – Shao, Y. – Qin, H. F., et al.: ALK-rearrangement in non-small-cell lung cancer (NSCLC). *Thorac Cancer*, 2018, 9, s. 423–430.
- 7 Morris, S. W., et al.: Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. *Science*, 1994, 263, s. 1281–1284.
- 8 Soda, M. – Choi, Y. L. – Enomoto, M., et al.: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. *Nature*, 2007, 448, s. 561–566.
- 9 Hallberg, B. – Palmer, R. H.: The role of the ALK receptor in cancer biology. *An Oncol*, 2016, 27, suppl. 3, s. iii4–iii15.
- 10 Guan, J. – Umaphathy, G. – Yamazaki, Y., et al.: FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase. *Elife*, 2015, 4, e09811.
- 11 Bayliss, R. – Choi, J. – Fennell, D. A., et al.: Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs. *Cell Mol Life Sci*, 2016, 73, s. 1209–1224.
- 12 Lin, J. J. – Riey, G. J. – Shaw, A. T., et al.: Precision medicine takes on drug resistance. *Cancer Discov*, 2017, 7, s. 137–155.
- 13 Chiarle, R. – Voena, C. – Ambrogio, C., et al.: The anaplastic lymphoma kinase in the pathogenesis of cancer. *Nat Rev Cancer*, 2008, 8, s. 11–23.
- 14 Sehgal, K. – Patell, R. – Rangachari, D., et al.: Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors. *Transl Cancer Res*, 2018, 7, suppl. 7, s. S779–S786.
- 15 Shaw, A. T. – Ou, S. H. – Bang, Y. J., et al.: Crizotinib in ROS1-rearranged non-small-cell lung cancer. *N Engl J Med*, 2014, 371, s. 1963–1971.
- 16 Hofman, P.: ALK in non-small cell lung cancer (NSCLC) pathobiology, epidemiology, detection from tumor tissue and algorithm diagnosis in a daily practice. *Cancers (Basel)*, 2017, 9, s. 107.
- 17 Le, T. – Gerber, D. E.: ALK alterations and inhibition in lung cancer. *Semin Cancer Biol*, 2017, 42, s. 81–88.
- 18 Shaw, A. T. – Yeap, B. Y. – Mino-Kenudson, M., et al.: Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. *J Clin Oncol*, 2009, 27, s. 4247–4253.
- 19 Yang, P. – Kulig, K. – Boland, J. M., et al.: Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma. *J Thorac Oncol*, 2012, 7, s. 90–97.
- 20 Barlesi, F. – Mazieres, J. – Merlio, J. P., et al.: Routine molecular profiling of patients with advanced non-small-cell lung cancer: Results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). *Lancet*, 2016, 387, s. 1415–1426.
- 21 Bergethon, K. – Shaw, A. T. – Ou, S. H., et al.: ROS1 rearrangements define a unique molecular class of lung cancers. *J Clin Oncol*, 2012, 30, s. 863–870.
- 22 Warth, A. – Muley, T. – Dienemann, H., et al.: ROS1 expression and translocations in non-small-cell lung cancer: clinicopathological analysis of 1478 cases. *Histopathology*, 2014, 65, s. 187–194.
- 23 Huber, K. V. – Salah, E. – Radic, B., et al.: Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. *Nature*, 2014, 508, s. 222–227.
- 24 Kazandjian, D. – Blumenthal, G. M. – Chen, H. Y., et al.: FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements. *Oncologist*, 2014, 19, s. e5–e11.
- 25 Dostupné z: <https://www.ema.europa.eu>, vyhledáno 4. 6. 2019.
- 26 Shaw, A. T. – Dong-Wan, K. – Nakagawa, K., et al.: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. *N Engl J Med*, 2013, 368, s. 2385–2394.
- 27 Solomon, B. J. – Mok, T. – Kim, D. W., et al.: First-line crizotinib versus chemotherapy in ALK-positive lung cancer. *New Eng J Med*, 2014, 371, s. 2167–2177.
- 28 Sharma, G. G. – Mota, I. – Mologni, L., et al.: Tumor resistance against ALK targeted therapy-where it comes from and where it goes. *Cancers (Basel)*, 2018, 10, s. 62.
- 29 Rothenstein, J. M. – Chooback, N.: ALK inhibitors, resistance development, clinical trials. *Curr Oncol*, 2018, 25, suppl. 1, s. S59–S67.
- 30 Sullivan, I. – Planchard, D.: ALK inhibitors in non-small cell lung cancer: the latest evidence and developments. *Ther Adv Med Oncol*, 2016, 8, s. 32–47.
- 31 Shaw, A. T. – Solomon, B. – Lilienbaum, R. C., et al.: Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer, dostupné z: <https://www.uptodate.com/contents/anaplastic-lymphoma-kinase-alk-fusion-oncogene-positive-non-small-cell-lung-cancer>, vyhledáno 4. 6. 2019.
- 32 Gainor, J. F. – Dardaei, L. – Yoda, S., et al.: Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. *Cancer Discov*, 2016, 6, s. 1118–1133.
- 33 Shaw, A. T. – Friboulet, L. – Leshchiner, I., et al.: Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F. *N Engl J Med*, 2016, 374, s. 54–61.
- 34 Le, T. – Gerber, D. E.: ALK alterations and inhibition in lung cancer. *Semin Cancer Biol*, 2017, 42, s. 81–88.
- 35 Shaw, A. T. – Felip, E. – Bauer, T. M., et al.: Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. *Lancet Oncol*, 2017, 18, s. 1590–1599.
- 36 Solomon, B. J. – Besse, B. – Bauer, T. M., et al.: Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. *Lancet Oncol*, 2018, 19, s. 1654–1667.
- 37 Dostupné z: [http://ec.europa.eu/health/documents/community-register/2019/20190506144341/anx\\_144341\\_cs.pdf](http://ec.europa.eu/health/documents/community-register/2019/20190506144341/anx_144341_cs.pdf), vyhledáno 17. 6. 2019.
- 38 Desai, A. – Sriwastava, S. – Gadgeel, S. M., et al.: New onset myasthenia gravis in a patient with non small cell lung cancer treated with lorlatinib a novel anti-cancer agent. *J Neurol Sci*, 2018, 392, s. 100–101.
- 39 Chabrol, A. – Mayenga, M. – Hamid, A. M., et al.: Lorlatinib – Induced pulmonary arterial hypertension. *Lung Cancer*, 2018, 120, s. 60–61.
- 40 Pacheco, J. P. – Gao, D. – Smith, D., et al.: Natural history and factors associated with overall survival in stage IV ALK-rearranged non-small cell lung cancer. *J Thorac Oncol*, 2019, 14, s. 691–700.

## Nový algoritmus léčby pokročilého NSCLC

doc. MUDr. Milada Zemanová, Ph.D. Onkologická klinika 1. LF UK a VFN, Praha

- 1 ÚZIS ČR, NOR ČR 2015, Novotvary 2015, Cancer Incidence 2015 in the Czech Republic.
- 2 Curran, W. J. Jr. – Paulus, R. – Langer, C. J., et al.: Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. *J Natl Cancer Inst*, 2011, 103, s. 1452–1460.
- 3 Aupérin, A. – LePêchoux, C. – Rolland, E., et al.: Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. *J Clin Oncol*, 2010, 28, s. 2181–2190.
- 4 Antonia, S. J. – Villegas, A. – Daniel, D., et al.: PACIFIC Investigators: Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. *N Engl J Med*, 2018, 379, s. 2342–2350.
- 5 Mok, T. S. – Wu, Y. L. – Thongprasert, S., et al.: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med*, 2009, 361, s. 947–957.
- 6 Lee, C. K. – Davies, L. – Wu, Y. L., et al.: Gefitinib or erlotinib vs chemotherapy for EGFR mutation-positive lung cancer: individual patient data meta-analysis of overall survival. *J Natl Cancer Inst*, 2017, 109.
- 7 Yang, J. C. – Wu, Y. L. – Schuler, M., et al.: Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung3 and LUX-Lung6): analysis of overall survival data from two randomised, phase 3 trials. *Lancet Oncol*, 2015, 16, s. 141–151.
- 8 Soria, J. C. – Ohe, Y. – Vansteenkiste, J., et al.: FLAURA Investigators: Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. *N Engl J Med*, 2018, 378, s. 113–125.
- 9 Wu, Y. L. – Cheng, Y. – Zhou, X., et al.: Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. *Lancet Oncol*, 2017, 18, s. 1454–1466.
- 10 Kato, T. – Seto, T. – Nishio, M., et al.: Erlotinib plus bevacizumab phase II study in patients with advanced non-small-cell lung cancer (J025567): updated safety results. *Drug Saf*, 2018, 41, s. 229–237.
- 11 Mok, T. S. – Wu, Y. L. – Ahn, M. J., et al.: Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. *N Engl J Med*, 2017, 376, s. 629–640.
- 12 Solomon, B. J. – Mok, T. – Kim, D. W., et al.: PROFILE 1014 Investigators: First-line crizotinib versus chemotherapy in ALK-positive lung cancer. *N Engl J Med*, 2014, 371, s. 2167–2177.
- 13 Shaw, A. T. – Kim, T. M. – Crinò, L., et al.: Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. *Lancet Oncol*, 2017, 18, s. 874–886.
- 14 Camidge, D. R. – Dziadziuszko, R. – Peters, S., et al.: Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study. *J Thorac Oncol*, 2019, pii: S1556-0864, s. 30210–30212.
- 15 Kim, D. W. – Tiseo, M. – Ahn, M. J., et al.: Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial. *J Clin Oncol*, 2017, 35, s. 2490–2498.
- 16 Solomon, B. J. – Besse, B. – Bauer, T. M., et al.: Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. *Lancet Oncol*, 2018, 19, s. 1654–1667, doi: 10.1016/S1470-2045(18)30649-1, Epub 6. 11. 2018, erratum in: *Lancet Oncol*, 2019, 20, e10.
- 17 Planchard, D. – Smit, E. F. – Groen, H. J. M., et al.: Dabrafenib plus trametinib in patients with previously untreated BRAF V600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. *Lancet Oncol*, 2017, 18, s. 1307–1316.
- 18 Joshi, A. – Pande, N. – Noronha, V., et al.: ROS1 mutation non-small cell lung cancer – access to optimal treatment and outcomes. *E Cancer Medical Science*, 2019, 13, s. 900.
- 19 Reck, M. – Rodríguez-Abreu, D. – Robinson, A. G., et al.: KEYNOTE-024 Investigators: Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. *N Engl J Med*, 2016, 375, s. 1823–1833.
- 20 Gandhi, L. – Rodríguez-Abreu, D. – Gadgeel, S., et al.; KEYNOTE-189 Investigators: Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. *N Engl J Med*, 2018, 378, s. 2078–2092.
- 21 Reck, M. – von Pawel, J. – Zatloukal, P., et al.: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for non squamous non-small-cell lung cancer: AVAIL. *J Clin Oncol*, 2009, 28, s. 1227–1234.
- 22 Sculier, J. – Pand Moro-Sibilot, D.: First-and second-line therapy for advanced non small cell lung cancer. *Eur Respir J*, 2009, 33, s. 915–930.
- 23 Scagliotti, G. V. – Parikh, P. – Pavel, J., et al.: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. *J Clin Oncol*, 2008, 26, s. 3543–3551.
- 24 Lee, D. H.: Treatments for EGFR-mutant non-small-cell lung cancer (NSCLC): The road to a success, paved with failures. *Pharmacol Ther*, 2017, 174, s. 1–21.
- 25 Gadgeel, S. – Peters, S. – Mok, T., et al.: Alectinib versus crizotinib in treatment-naïve anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. *Ann Oncol*, 2018, 29, s. 2214–2222.
- 26 Thatcher, N. – Hirsch, F. R. – Luft, A. V., et al.; SQUIRE Investigators: Nectinumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. *Lancet Oncol*, 2015, 16, s. 763–774.
- 27 Gerber, D. E. – Schiller, J. H.: Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea. *J Clin*

- Oncol*, 2013, 31, s. 1009–1020.
- Paz-Ares, L. – de Marinis, F., et al.**: Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. *Lancet Oncol*, 2012, 13, s. 247–255.
  - Reck, M. – von Pawel, J. – Zatloukal, P., et al.**: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for non-squamous non-small-cell lung cancer. *AWAil. J Clin Oncol*, 2009, 28, 1227–1234.
  - Socinski, M. A. – Jotte, R. M. – Cappuzzo, F., et al.**: IMpower150 Study Group: Atezolizumab for first-line treatment of metastatic non-squamous NSCLC. *N Engl J Med*, 2018, 378, s. 2288–2301.
  - Pacheco, J. M. – Camidge, D. R. – Doebele, R. C., et al.**: Changing of the guard: immune checkpoint inhibitors with and without chemotherapy as first line treatment for metastatic non-small cell lung cancer. *Front Oncol*, 2019, 9, s. 195.
  - Brahmer, J. – Reckamp, K. L. – Baas, P., et al.**: Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. *N Engl J Med*, 2015, 373, s. 123–135.
  - Herbst, R. S. – Baas, P. – Kim, D. W., et al.**: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. *Lancet*, 2016, 387, s. 1540–1550.
  - Rittmeyer, A. – Barlesi, F. – Waterkamp, D., et al.**: OAK Study Group: Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. *Lancet*, 2017, 389, s. 255–265.
  - Scagliotti, G.**: An evaluation of pemetrexed in second-line treatment of non-small cell lung cancer. *Expert Opin Pharmacother*, 2005, 6, s. 2855–2866.
  - Reck, M. – Kaiser, R. – Mellemegaard, A., et al.**: LUME-Lung 1 Study Group: Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. *Lancet*, 2014, 15, s. 143–155.
  - Garon, E. B. – Ciuleanu, T. E. – Arrieta, O., et al.**: Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. *Lancet*, 2014, 384, s. 665–673.
  - Shepherd, F. A. – Pereira, J. R. – Ciuleanu, T., et al.**: Erlotinib in previously treated non-small-cell lung cancer. *N Engl J Med*, 2005, 353, s. 123–132.
  - Soria, J. – Felip, E. – Cobo, M., et al.**: Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. *Lancet Oncol*, 2015, 16, s. 897–907.
  - Hirsch, F. R. – Spreafico, A. – Novello, S., et al.**: The Prognostic and Predictive role of histology in advanced non-small-cell lung cancer. *J Thorac Oncol*, 2008, 3, s. 1468–1481.
  - Sculier, J. – Pand Moro-Sibilot, D.**: First-and second-line therapy for advanced non-small-cell lung cancer. *Eur Respir J*, 2009, 33, s. 915–930.

## Co nového v imunoterapii na WCLC 2019

MUDr. Leona Koubková Pneumologická klinika UK 2. LF a FN Motol, Praha

- Gettinger, S. – Borghaei, H. – Brahmer, J., et al.**: Five-Year Outcomes from the Randomized, Phase 3 Trials CheckMate 017/057: Nivolumab vs Docetaxel in Previously Treated NSCLC. Abstrakt OA14.04 prezentován 10. 9. 2019 na IASLC 2019 World Conference on Lung Cancer, Barcelona, Španělsko, [www.wclc2019.iascl.org](http://www.wclc2019.iascl.org).
- Reck, M. – Rodríguez-Abreu, D. – Robinson, A. G., et al.**: KEY-NOTE-024 3-Year Survival Update: Pembrolizumab vs Platinum Based Chemotherapy for Advanced Non-Small Cell Lung Cancer. Abstrakt OA14.01 prezentován 10. 9. 2019 na IASLC 2019 World Conference on Lung Cancer, Barcelona, Španělsko, [www.wclc2019.iascl.org](http://www.wclc2019.iascl.org).
- Garassino, M.**: PRO: Chemotherapy is necessary. Abstrakt PC04.01 prezentován 10. 9. 2019 na IASLC 2019 World Conference on Lung Cancer, Barcelona, Španělsko, [www.wclc2019.iascl.org](http://www.wclc2019.iascl.org).
- Reck, M.**: CON: ICI is Enough. Abstrakt PC04.02 prezentován 10. 9. 2019 na IASLC 2019 World Conference on Lung Cancer, Barcelona, Španělsko, [www.wclc2019.iascl.org](http://www.wclc2019.iascl.org).
- Garassino, M. – Rodríguez-Abreu, D. – Gadgeel, S., et al.**: Evaluation of TMB in KEYNOTE-189: Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy for Nonsquamous NSCLC. Abstrakt OA04.06 prezentován 8. 9. 2019 na IASLC 2019 World Conference on Lung Cancer, Barcelona, Španělsko, [www.wclc2019.iascl.org](http://www.wclc2019.iascl.org).
- Jotte, R. – Cappuzzo, F. – Vynnychenko, I., et al.**: IMpower 131: Final OS Results of Carboplatin + Nab paclitaxel ± Atezolizumab in Advanced Squamous NSCLC. Abstrakt OA14.02 prezentován 10. 9. 2019 na IASLC 2019 World Conference on Lung Cancer, Barcelona, Španělsko, [www.wclc2019.iascl.org](http://www.wclc2019.iascl.org).
- Provencio, M. – Nadal, E. – Insa, A., et al.**: NADIM Study: Updated Clinical Research and Outcomes. Abstrakt OA13.05 prezentován 10. 9. 2019 na IASLC 2019 World Conference on Lung Cancer, Barcelona, Španělsko, [www.wclc2019.iascl.org](http://www.wclc2019.iascl.org).
- Sepesi, B. – Cascone, T. – William, W., et al.**: Surgical Outcomes Following Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Non-Small Cell Lung Cancer – NEOSTAR Study. Abstrakt OA13.06 prezentován 10. 9. 2019 na IASLC 2019 World Conference on Lung Cancer, Barcelona, Španělsko, [www.wclc2019.iascl.org](http://www.wclc2019.iascl.org).
- Park, S. – Jung, H. A. – Cho, J. H., et al.**: Adjuvant Pembrolizumab in N2 positive NSCLC Treated with Concurrent Chemoradiotherapy Followed by Surgery: Phase II, Prospective Study. Abstrakt MA08.03 prezentován 8. 9. 2019 na IASLC 2019 World Conference on Lung Cancer, Barcelona, Španělsko, [www.wclc2019.iascl.org](http://www.wclc2019.iascl.org).
- Lee, J. – Chaff, J. – Nicholas, A., et al.**: Surgical Outcomes of a Multicenter Phase II Trial of Neoadjuvant Atezolizumab in Resectable Stages IB-IIIb NSCLC: Update on LCMC3 Clinical Trial. Abstrakt P2.04-88 prezentován 10. 9. 2019 na IASLC 2019 World Conference on Lung Cancer, Barcelona, Španělsko, [www.wclc2019.iascl.org](http://www.wclc2019.iascl.org).
- Ramirez, J.**: Major Pathological Evaluation in Neoadjuvant Immunotherapy. Abstrakt MS17.02 prezentován 10. 9. 2019 na IASLC 2019 World Conference on Lung Cancer, Barcelona, Španělsko, [www.wclc2019.iascl.org](http://www.wclc2019.iascl.org).
- Paz-Ares, L. – Chen, Y. – Reinmuth, N., et al.**: Overall Survival with Durvalumab plus Etoposide-Platinum in First Line Extensive Stage SCLC: Results from the CASPIAN Study. Abstrakt PL02.11 prezentován 9. 9. 2019 na IASLC 2019 World Conference on Lung Cancer, Barcelona, Španělsko, [www.wclc2019.iascl.org](http://www.wclc2019.iascl.org).

## Léčba kolorektálního karcinomu ve druhé linii

Rozhovor Mgr. Dany Frantálové s MUDr. Radmilou Lemstrovou, doc. MUDr. Tomášem Büchlerem, Ph.D., MUDr. Petrou Klimčíkovou, MUDr. Jiřím Tomáškem, Ph.D., MUDr. Stanislavem Johnem a MUDr. Zdeňkem Linkem

- Bennouna, J. – Sastre, J. – Arnold, D., et al.**: Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. *Lancet Oncol*, 2013, 14, s. 29–37.
- Giantonio, B. J. – Catalano, P. J. – Meropol, N. J., et al.**: Bevacizumab in combination with fluorouracil, oxaliplatin, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study (E 3200). *J Clin Oncol*, 2007, 25, s. 1539–1544.
- Ottiano, A. – Capozzi, M. – Tafuto, S., et al.**: Folfiri-afibercept versus Folfiri-bevacizumab as second line treatment of RAS mutated metastatic colorectal cancer in real practice. *Front Oncol*, 2019, 9, s. 766.

## Zkušenosti s bevacizumabem v první a druhé linii terapie pacientky s metastazujícím karcinomem rekta – kazuistika

MUDr. Michal Vočka Onkologická klinika, 1. LF UK a VFN, Praha

- Systém pro vizualizaci onkologických dat – SVOD. Dostupné z: [www.svod.cz](http://www.svod.cz), vyhledáno 30. 4. 2018.
- Van Cutsem, E. – Cervantes, A. – Adam, R., et al.**: ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. *Ann Oncol*, 2016, 27, s. 1386–1422.
- Benson, A. B. 3rd. – Venook, A. P. – Cederquist, L., et al.**: Colon cancer, version 1.2017, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*, 2019, 15, s. 370–398.
- Temmink, O. H. – Emura, T. – de Bruin, M., et al.**: Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies. *CancerSci*. 2007;98:779–789.

## Tromboembolické komplikace u onkologických pacientů a jejich primární profylaxe

prof. MUDr. Jan Kvasnička, DrSc. Trombotické centrum ÚLBLD a I. interní klinika VFN a 1. LF UK, Praha

- Noble, S. – Pasi, J.**: Epidemiology and pathophysiology of cancer-associated thrombosis. *Br J Cancer*, 2010, 102, suppl. 1, s. S2–S9.
- Cohen, A. T. – Agnelli, G. – Anderson, F. A., et al.**: Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. *Thromb Haemost*, 2007, 98, s. 756–764.
- Lyman, G. H.**: Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. *Cancer*, 2011, 117, s. 1334–1349.
- Cronin-Fenton, D. P. – Søndergaard, F. – Pedersen, L. A., et al.**: Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997–2006. *Br J Cancer*, 2010, 103, s. 947–953.
- Kakkar, A. K. – Levine, M. – Pinedo, H. M., et al.**: Venous thrombosis in cancer patients: insights from the FRONTLINE survey. *Oncologist*, 2003, 8, s. 381–388.
- Khorana, A. A. – Francis, C. W. – Culakova, E., et al.**: Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. *J Thromb Haemost*, 2007, 5, s. 632–634.
- Kasthuri, R. S. – Taubman, M. B. – Mackman, N.**: Role of tissue factor in cancer. *J Clin Oncol*, 2009, 27, s. 4834–4838.
- van den Berg, Y. W. – Osanto, S. – Reitsma, P. H., et al.**: The relationship between tissue factor and cancer progression: insights from bench and bedside. *Blood*, 2012, 119, s. 924–932.
- Ruf, W. – Disse, J. – Carneiro-Lobo, T. C., et al.**: Tissue factor and cell signalling in cancer progression and thrombosis. *J Thromb Haemost*, 2011, 9, suppl. 1, s. 306–315.
- Wahrenbrock, M. – Borsig, L. – Le, D., et al.**: Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. *J Clin Invest*, 2003, 112, s. 853–862.
- Labelle, M. – Begum, S. – Hynes, R. O.**: Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. *Cancer Cell*, 2011, 20, s. 576–590.

- Zwicker, J. I. – Liebman, H. A. – Bauer, K. A.: Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial the Microtec study. *Br J Haematol*, 2013, 160, s. 530–537.
- Penka, M.: Aktivace krevního srážení u onkologicky nemocných. *Vnitřní lékařství*, 1997, 43, s. 337–339.
- Sud, R. – Khorana, A. A.: Cancer-associated thrombosis: risk factors, candidate biomarkers and a risk model. *Thromb Res*, 2009, 4, s. S18–S21.
- Khorana, A. A. – Kuderer, N. M. – Culakova, E., et al.: Development and validation of a predictive model for chemotherapy-associated thrombosis. *Blood*, 2008, 111, s. 4902–4907.
- Ay, C. – Simanek, R. – Vormittag, R., et al.: High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). *Blood*, 2008, 112, s. 2703–2708.
- Khorana, A. A. – O'Connell, C. – Agnelli, G., et al.: Incidental venous thromboembolism in oncology patients. *J Thromb Haemost*, 2012, 10, s. 2602–2604.
- Blom, J. W. – Doggen, C. J. – Osanto, S., et al.: Malignancies, prothrombotic mutations, and the risk of venous thrombosis. *JAMA*, 2005, 293, s. 715–722.
- Farge, D. – Debourdeau, P. – Beckers, M., et al.: International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. *J Thromb Haemost*, 2013, 11, s. 56–70.
- Tun, N. M. – Guevara, E. – Oo, Th.: Benefit and risk thromboprophylaxis in ambulatory patients with advanced pancreatic cancer receiving chemotherapy: a systematic review and meta-analysis of randomized controlled trials. *Blood Coagul Fibrinolysis*, 2016, 27, s. 270–274.
- Farge, D. – Frere, C. – Connors, J. M., et al.: International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. *Lancet Oncol*, 3. 9. 2019, pii: S1470-2045(19)30336–30335.
- Státní ústav pro kontrolu léčiv. Dostupné z: www.sukl.cz, vyhledáno 18. 9. 2019.
- ENOXACAN Study Group: Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. *Br J Surg*, 1997, 84, s. 1099–1103.
- Samama, M. M. – Cohen, A. T. – Darmon, J. Y., et al.: A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. *N Engl J Med*, 1999, 341, s. 793–800.
- Alikhan, R. – Cohen, A. T. – Combe, S., et al.: Prevention of venous thromboembolism in medical patients with enoxaparin: a sub group analysis of the MEDENOX study. *Blood Coagul Fibrinolysis*, 2003, 14, s. 341–346.
- Agnelli, G. – Gussoni, G. – Bianchini, C., et al.: PROTECT Investigators: Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. *Lancet Oncol*, 2009, 10, s. 943–949.
- Khorana, A. A. – Soff, G. A. – Kakkar, A. K., et al.: for the CASSINI Investigators: Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. *N Engl J Med*, 2019, 380, s. 720–728.
- Carrier, M. – Abou-Nassar, K. – Tagalakis, V., et al.; for the AVERT Investigators: Apixaban to prevent venous thromboembolism in patients with cancer. *N Engl J Med*, 2019, 380, s. 711–719.
- Zamorano, J. L. – Lancellotti, P. – Muñoz, D., et al.: 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). *European Heart Journal*, 2016, 37, s. 2768–2801.
- Wells, P. S. – Anderson, D. R. – Rodger, M., et al.: Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. *N Engl J Med*, 2003, 349, s. 1227–1235.
- Samama, M. M. – Dahl, O. E. – Quinlan, D. J., et al.: Quantification of risk factors for venous thromboembolism: a preliminary study for the development of a risk assessment tool. *Haematologica*, 2003, 88, s. 1410–1421.

## Léčebné konopí

MUDr. Marek Hák, Ph.D. Centrum léčby bolesti, Medicinare, s. r. o., Chirurgická klinika FN a LF MU, Brno

- Devane, W. A. – Hanuš, L. – Breuer, A., et al.: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. *Science*, 1992, 258, s. 1946–1949.
- DiMarzo, V. – Wang, J.: *The Endocannabinoid system. The World of Endocannabinoids and Related Medicators*. Academic Press, 2014.

## Možnosti léčby nádorové bolesti

MUDr. Jan Lejško Centrum pro léčbu bolesti Anesteziologicko-resuscitační kliniky FN Plzeň

- WHO: *Cancer pain relief: report of a WHO expert committee*. 2. vydání, WHO, 1996.
- Kolektiv autorů: *Metodické pokyny pro farmakoterapii bolesti*. Bolest, 2009, suppl. 2.
- Rokyta, R. – Kršík, M. – Kozák, J.: *Bolest*. Tigris, Praha, 2012.
- Higginson, I. J. – Hearn, J. – Addington-Hall, J.: In: Sykes, N. – Fallon, M. T. – Patt, R. B.: *Clinical Pain Management-Cancer Pain*. Londýn, Arnold, 2003, s. 21–32.
- Watson, C. P. – Moulin, D. – Watt-Watson, J., et al.: Controlled-release oxycodone relieves neuropathic pain: a randomised controlled trial in painful diabetic neuropathy. *Pain*, 2003, 105, s. 71–78.
- Ahmedzai, S. – Brooks, D.: Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. *J Pain Symptom Manage*, 1997, 13, s. 254–261.
- Portenoy, R. K., et al.: Oral transmucosal fentanyl (OTFC) for the treatment of breakthrough pain in cancer patients. *Pain*, 1999, 79, s. 303–312.

## Národní onkologické programy: klíč ke zlepšení onkologické péče – Annual Cancer Media Summit

- Joint Action of Cancer Patient Organizations (JACPO). Results of the first survey on the expected outcomes of oncology patient care in 12 Central and Eastern European countries, 2019. Dostupné z: [http://www.onkologija.hr/wp-content/uploads/2019/06/results\\_all\\_countries.pdf](http://www.onkologija.hr/wp-content/uploads/2019/06/results_all_countries.pdf), vyhledáno 24. 9. 2019.
- Vrdoljak, E. – Bodoky, G. – Jassem, J., et al.: Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement. *Oncologist*, 2016, 21, s. 1183–1190.
- The World Bank. Data Bank. World Development Indicators. 2016. Dostupné z: <http://databank.worldbank.org/source/world-development-indicators>.
- Luengo-Fernandez, R. – Leal, J. – Gray, A. – Sullivan, R.: Economic burden of cancer across the European Union: a population-based cost analysis. *Lancet Oncol*, 2013, 14, s. 1165–1174.

## CAR-T lymfocyty v léčbě B-buněčných lymfomů

MUDr. Pavel Otáhal, Ph.D. | prof. MUDr. Marek Trněný, DrSc. I. interní klinika 1. LF a VFN, Praha

- Gross, G. – Waks, T. – Eshhar, Z.: Expression of immunoglobulin – T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. *Proc Natl Acad Sci U S A*, 1989, 86, s. 10024–10028.
- Schuster, S. J. – Bishop, M. R. – Tam, C. S., et al.; JULIET Investigators: Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. *N Engl J Med*, 2019, 380, s. 45–56.
- Locke, F. L. – Ghobadi, A. – Jacobson, C. A., et al.: Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. *Lancet Oncol*, 2019, 20, s. 31–42.
- Havard, R. – Stephens, D. M.: Anti-CD19 chimeric antigen receptor T cell therapies: harnessing the power of the immune system to fight diffuse large B cell lymphoma. *Curr Hematol Malig Rep*, 2018, 13, s. 534–542.
- Crump, M. – Neelapu, S. S. – Faraoui, U., et al.: Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. *Blood*, 2017, 130, s. 1800–1808.
- Kochenderfer, J. N. – Dudley, M. E. – Kassim, S. H., et al.: Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. *J Clin Oncol*, 2015, 33, s. 540–549.

## Immune checkpoint inhibitory v léčbě Hodgkinova lymfomu

MUDr. Veronika Hanáčková | doc. MUDr. Vít Procházka, Ph.D. Hemato-onkologická klinika, FN Olomouc a LF UP, Olomouc

- Novotary 2016 ČR. Praha, Ústav zdravotnických informací a statistiky ČR, 2016, s. 102–110.
- Klimm, B. – Goergen, H. – Fuchs, M., et al.: Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: an analysis of international staging definitions. *Ann Oncol*, 2013, 24, s. 3070–3076.
- Kooperativní lymfomová skupina: *Diagnostické a léčebné postupy u nemocných s maligními lymfomy – X. vydání*. HK CREDIT, Hradec Králové, 2018.
- Fuchs, M. – Goergen, H. – Kobe, C.: PET-guided treatment of early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase 3 trial HD16 by the German Hodgkin Study Group. Abstract 925. ASH 2018.
- Dostupné z: <http://www.sukl.cz/modules/medication-Adcetris> – souhrn údajů o přípravku, vyhledáno 20. 3. 2019.
- Green, M. R. – Monti, S. – Rodig, S. J., et al.: Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. *Blood*, 2010, 116, s. 3268–3277.
- Mahoney, K. M. – Freeman, G. J. – McDermott, D. F.: The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma. *Clin Ther*, 2015, 37, s. 764–782.
- Herbst, R. S. – Baas, P. – Kim, D. W., et al.: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. *Lancet*, 2016, 387, s. 1540–1550.
- Ansell, M. – Lesokhin, A. – Borrello, I., et al.: PD-1 blockade with



- nivolumab in relapsed or refractory Hodgkin's lymphoma. *N Engl J Med*, 2015, 372, s. 311–319.
- 10 Younes, A. – Santoro, A. – Shipp, M., et al.: Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and Brentuximab Vedotin: a multicentre, multicohort, single-arm phase 2 trial. *Lancet Oncol*, 2016, 17, s. 1283–1294.
  - 11 Armand, P. – Engert, A. – Younes, A., et al.: Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. *J Clin Oncol*, 2018, 36, s. 1428–1439.
  - 12 Dostupné z: <http://www.sukl.cz/modules/medication> – Opdivo – souhrn údajů o přípravku, vyhledáno 20. 3. 2019.
  - 13 Dostupné z: [www.sukl.cz/modules/medication](http://www.sukl.cz/modules/medication) – Keytruda – souhrn údajů o přípravku, vyhledáno 6. 5. 2019.
  - 14 Armand, P. – Shipp, M. A. – Ribrag, V., et al.: Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. *J Clin Oncol*, 2016, 34, s. 3733–3739.
  - 15 Armand, P. – Shipp, M. A. – Ribrag, V., et al.: Pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: long-term efficacy from the phase 1b Keynote-013 Study. *Blood*, 2016, 128, s. 1108.
  - 16 Chen, R. – Zinzani, P. L. – Fanale, M. A., et al.: Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. *J Clin Oncol*, 2017, 35, s. 2125–2132.
  - 17 Chen, R. – Ribb, A. – Collins, G. P., et al.: Blockade of the PD-1 checkpoint with anti-PD-L1 antibody avelumab is sufficient for clinical activity in relapsed/refractory classical Hodgkin lymphoma. *Hematol Oncol*, 2017, 35, suppl. 2, s. 67.
  - 18 Qin, Q. – Nan, X. – Miller, T., et al.: Complete local and abscopal responses from a combination of radiation and nivolumab in refractory Hodgkin's lymphoma. *Radiat Res*, 2018, 190, s. 322–329.
  - 19 Baues, C. – Trommer-Nestler, M. – Jablonska, K., et al.: Short review of potential synergies of immune checkpoint inhibition and radiotherapy with a focus on Hodgkin lymphoma: radio-immunotherapy opens new doors. *Immunotherapy*, 2017, 9, s. 423–433.
  - 20 Ansell, S. M.: The highs and lows of immune-checkpoint blockade in lymphoma. *Cancer Immunol Res*, 2019, 7, s. 696–700.

## Konjugované monoklonální protilátky v léčbě lymfomů

MUDr. Jan Kořen I. interní klinika – klinika hematologie, 1. LF UK a VFN, Praha

- 1 Beck, A. – Goetsch, L. – Dumontet, C., et al.: Strategies and challenges for the next generation of antibody-drug conjugates. *Nat Rev Drug Discov*, 2017, 16, s. 3153–3177.
- 2 Godwin, C. D. – Gale, R. P. – Walter, R. B.: Gemtuzumab ozogamicin in acute myeloid leukemia. *Leukemia*, 2017, 31, s. 1855–1868.
- 3 Jen, E. Y. – Ko, C. W. – Lee, J. E., et al.: FDA approval: Gemtuzumab ozogamicin for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia. *Clin Cancer Res*, 2018, 24, s. 3242–3246.
- 4 Yi, J. H. – Kim, S. J. – Kim, W. S.: Brentuximab vedotin: Clinical updates and practical guidance. *Blood Res*, 2017, 52, s. 243–253.
- 5 Lamb, Y. N.: Inotuzumab ozogamicin: First global approval. *Drugs*, 2017, 77, s. 1603–1610.
- 6 Kovtun, Y. V., et al.: Antibody–drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. *Cancer Res*, 2006, 66, s. 3214–3221.
- 7 Polson, A. G., et al.: Investigational antibody-drug conjugates for hematological malignancies. *Expert Opin Investig Drugs*, 2011, 20, s. 75–85.
- 8 Lambert, J. M. – Berkenblit, A.: Antibody-drug conjugates for cancer treatment. *Annu Rev Med*, 2018, 69, s. 191–207.
- 9 Araí, S. – Fanale, M. – DeVos, S., et al.: Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. *Leuk Lymphoma*, 2013, 54, s. 2531–2533.
- 10 Crump, M.: Management of Hodgkin lymphoma in relapse after autologous stem cell transplant. *hematology*. *Am Soc Hematol Educ Program*, 2008, s. 326–333.
- 11 Chen, R. – Gopal, A. K. – Smith, S. E., et al.: Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. *Blood*, 2016, 128, s. 1562–1566.
- 12 Sweetenham, J. – Walewski, J. – Nademanee, A. P., et al.: Update efficacy and safety data from the AETHERA trial of consolidation with brentuximab vedotin after autologous stem cell transplant (ASCT) in Hodgkin lymphoma patients at high risk of relapse. *Blood*, 2015, 126, s. 3172.
- 13 Moskowitz, A. J.: Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. *Blood*, 2010, 116, s. 4934–4937.
- 14 Chen, R. – Palmer, J. M. – Martin, P., et al.: Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed/refractory Hodgkin lymphoma. *Biol Blood Marrow Transplant*, 2015, 21, s. 2136–2140.
- 15 Michallet, A. S. – Guillermin, Y. – Deau, B., et al.: Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma. *Haematologica*, 2015, 100, s. e269–e271.
- 16 Moskowitz, A. J. – Schoder, H. – Yahalom, J., et al.: PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. *Lancet Oncol*, 2015, 16, s. 284–292.
- 17 LaCasce, A. S. – Bociek, G. – Sawas, A., et al.: Brentuximab vedotin plus bendamustine: a highly active salvage treatment regimen for patients with relapsed or refractory Hodgkin lymphoma. *Blood*, 2015, 126, s. 3982.
- 18 Garcia-Sanz, R. – Sureda, A. – Gonzalez, A. P., et al.: Brentuximab vedotin plus ESHAP (BESHAP) is a highly effective combination for induction remission in refractory and relapsed Hodgkin lymphoma patients prior to autologous stem cell transplant: a trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO). *Blood*, 2016, 128, s. 1109.
- 19 Herrera, A. F., et al.: Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. *Blood*, 2018, 131, s. 1183–1194.
- 20 Forero-Torres, A. – Holkova, B. – Goldschmidt, J., et al.: Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. *Blood*, 2015, 126, s. 2798–2804.
- 21 Gallamini, A. – Bijou, F. – Viotti, J., et al.: Brentuximab-vedotin and bendamustine is a feasible and effective drugs combination as first-line treatment of Hodgkin lymphoma in the elderly (HALO TRIAL). *Hematol Oncol*, 2017, 35, suppl. 2, s. 170.
- 22 Friedberg, J. W. – Forero-Torres, A. – Bordoni, R. E., et al.: Front-line brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged  $\geq 60$  years with HL. *Blood*, 2017, 130, s. 2829–2837.
- 23 Younes, A. – Connors, J. M. – Park, S. I., et al.: Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. *Lancet Oncol*, 2013, 14, s. 1348–1356.
- 24 Connors, J. M. – Ansell, S. – Fanale, M. A., et al.: Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma. *Blood*, 2017, 130, s. 1375–1377.
- 25 Connors, J. M. – Jurczak, W. – Straus, D. J., et al.: Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma. *N Engl J Med*, 2018, 378, s. 331–344.
- 26 Pro, B. – Advani, R. – Brice, P., et al.: Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. *J Clin Oncol*, 2012, 30, s. 2190–2196.
- 27 Fanale, M. A. – Horowitz, S. M. – Forero-Torres, A., et al.: Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas. *Blood*, 2018, 131, s. 2120–2124.
- 28 Horwitz, S., et al.: The ECHOLON-2 trial: results of a randomized, double-blind, active-controlled phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30+ peripheral T-cell lymphomas. Abstrakt 997, prezentováno na 2018 ASH Annual Meeting, 3. 12. 2018, San Diego, CA.
- 29 Matasar, M. – Herrera, A. F. – Kamdar, M., et al.: Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory FL or DLBCL: updated results of a phase 1b/2 study. *Hematol Oncol*, 2017, 35, s. 271–272.
- 30 Caimi, P., et al.: Safety and efficacy of Adct-402 (loncastuximab tesirine), a novel antibody drug conjugate, in relapsed/refractory follicular lymphoma and mantle cell lymphoma: interim results from the phase 1 first-in-human study. *Blood*, 2018, 132, suppl. 1, s. 2874.

## Léčba nehodgkinských lymfomů monoklonálními protilátkami v roce 2019

MUDr. David Belada, Ph.D. IV. interní hematologická klinika, FN HK a LF UK v Hradci Králové

- 1 Marcus, R. – Imrie, K. – Solal-Celigny, P., et al.: Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. *J Clin Oncol*, 2008, 26, s. 4579–4586.
- 2 Coiffier, B. – Lepage, E. – Briere, J., et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. *N Engl J Med*, 2002, 346, s. 235–242.
- 3 Salles, G. – Seymour, J. F. – Offner, F., et al.: Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. *Lancet*, 2011, 377, s. 42–51.
- 4 van Oers, M. H. – Van Glabbeke, M., et al.: Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. *J Clin Oncol*, 2010, 28, s. 2853–2858.
- 5 Kluin-Nelemans, H. C. – Doorduijn, J. K.: Treatment of elderly patients with mantle cell lymphoma. *Semin Hematol*, 2011, 48, s. 208–213.
- 6 Salari, A. – Avivi, I., et al.: Final results of the BP 22333 Study demonstrate non inferior pharmacokinetics and safety of subcutaneous versus intravenous rituximab as maintenance therapy for follicular lymphoma. *Hematol Oncol*, 2013, 31, s. 195.
- 7 Davies, A. – Merli, F. – Mihaljević, B.: Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. *Lancet Haematol*, 2017, 4, s. e272–e282.
- 8 Jurczak, W. – Moreira, I. – Kanakasetty, G. B., et al.: Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study. *Lancet Haematol*, 2017, 4, s. e350–e361.
- 9 Hiddemann, W. – Barbui, A. M. – Canales, M. A., et al.: Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety. *J Clin Oncol*, 2018, 36, s. 2395–2404.
- 10 Cheson, B. D. – Chua, N. – Mayer, J., et al.: Overall survival benefit in patients with rituximab-refractory indolent non-hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study. *J Clin Oncol*, 2018, 36, s. 2259–2266.
- 11 Vitolo, U. – Trněný, M. – Belada, D., et al.: Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. *J Clin Oncol*, 2017, 35, s. 3529–3537.

## Bispecifické protilátky v léčbě akutní lymfoblastové leukemie a lymfomů

MUDr. Kamila Polgárová | prof. MUDr. Marek Trněný, CSc. Interní klinika – klinika hematologie, 1. LF UK a VFN, Praha

- 1 Nisonoff, A. – Wissler, F. C. – Lipman, L. N.: Properties of the major component of a peptic digest of rabbit antibody. *Science*, 1960, 132, s. 1770–1771.
- 2 Nitta, T. – Sato, K. – Yagita, H., et al.: Preliminary trial of specific targeting therapy against malignant glioma. *Lancet*, 1990, 335, s. 368–371.
- 3 de Gaster, G. C., et al.: CD8 T cell activation after intravenous administration of CD3 x CD19 bispecific antibody in patients with non-Hodgkin lymphoma. *Cancer Immunol Immunother*, 1995, 40, s. 390–396.
- 4 Wurch, T. – Pierré, A. – Depil, S.: Novel protein scaffolds as emerging therapeutic proteins: from discovery to clinical proof-of-concept.

- Trends Biotechnol*, 2012, 30, s. 575–582.
- 5 **Mayrhofer, P. – Kunert, R.**: Nomenclature of humanized mAbs: Early concepts, current challenges and future perspectives. *Hum Antibodies*, 2018, 27, s. 37–51.
  - 6 **Sedykh, S. E. – Prinz, V. V. – Buneva, V. N., et al.**: Bispecific antibodies: design, therapy, perspectives. *Drug Des Devel Ther*, 2018, 12, s. 195–208.
  - 7 **Florio, M., et al.**: A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair. *Nat Commun*, 2016, 7, s. 11505.
  - 8 **Pipe, S. W., et al.**: Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. *Lancet Haematol*, 2019, 6, s. 295–305.
  - 9 **Kanodia, J. S., et al.**: Prospective design of anti-transferrin receptor bispecific antibodies for optimal delivery into the human brain. *CPT Pharmacometrics Syst Pharmacol*, 2016, 5, s. 283–291.
  - 10 **DiGiandomenico, A., et al.**: A multifunctional bispecific antibody protects against *Pseudomonas aeruginosa*. *Sci Transl Med*, 2014, 6, s. 262–155.
  - 11 **Wu, B., et al.**: Pharmacokinetics (PK) of blinatumomab and its clinical implications. *J Clin Oncol*, 2013, 31, s. 3048.
  - 12 **Viardot, A., et al.**: Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. *Blood*, 2016, 127, s. 1410–1416.
  - 13 **Topp, M. S., et al.**: Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. *J Clin Oncol*, 2011, 29, s. 2493–2498.
  - 14 **Topp, M. S., et al.**: Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. *Blood*, 2012, 120, s. 5185–5187.
  - 15 **Gökbuget, N., et al.**: Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. *Blood*, 2018, 131, s. 1522–1531.
  - 16 **Topp, M. S., et al.**: Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. *Lancet Oncol*, 2015, 16, s. 57–66.
  - 17 **Kantarjian, H., et al.**: Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. *N Engl J Med*, 2017, 376, s. 836–847.
  - 18 **Topp, M. S., et al.**: Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. *J Clin Oncol*, 2014, 32, s. 4134–4140.
  - 19 **von Stackelberg, A., et al.**: Phase I/Phase II Study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. *J Clin Oncol*, 2016, 34, s. 4381–4389.
  - 20 **Assi, R., et al.**: Safety and efficacy of blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed Philadelphia chromosome-positive leukemia. *Clin Lymphoma Myeloma Leuk*, 2017, 17, s. 897–901.
  - 21 **Martinelli, G., et al.**: Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. *J Clin Oncol*, 2017, 35, s. 1795–1802.
  - 22 **Goebeler, M.-E., et al.**: Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma: final results from a phase I study. *J Clin Oncol*, 2016, 34, s. 1104–1111.
  - 23 **Dufner, V. – Goebeler, M.-E. – Sayheli, C., et al.**: Bispecific T-cell engager antibody construct blinatumomab shows durable response in a long-term follow-up analysis of 38 NHL patients treated in a phase I trial. *Blood*, 2015, 126, s. 3974–3974.
  - 24 **Coyle, L., et al.**: Open-label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. *Blood*, 2018, 132, 400 LP-400.
  - 25 **Bannerji, R., et al.**: Emerging clinical activity of REGN1979, an anti-CD20 x anti-CD3 bispecific antibody, in patients with relapsed/refractory follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and other B-cell non-Hodgkin lymphoma (B-NHL) subtypes. *Blood*, 2018, 132, 1690 LP-1690.
  - 26 **Budde, L. E., et al.**: Mosunetuzumab, a full-length bispecific CD20/CD3 antibody, displays clinical activity in relapsed/refractory B-cell non-Hodgkin lymphoma (NHL): interim safety and efficacy results from a phase 1 study. *Blood*, 2018, 132, s. 399–399.
  - 27 **Rothe, A., et al.**: A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. *Blood*, 2015, 125, s. 4024–4031.
  - 28 **Barrett, D. M. – Teachey, D. T. – Grupp, S. A.**: Toxicity management for patients receiving novel T-cell engaging therapies. *Curr Opin Pediatr*, 2014, 26, s. 43–49.
  - 29 **Frey, N. V. – Porter, D. L.**: Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. *ASH Educ Progr B*, 2016, s. 567–572.
  - 30 **Grupp, S. A., et al.**: Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. *N Engl J Med*, 2013, 368, s. 1509–1518.
  - 31 **Davila, M. L., et al.**: Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. *Sci Transl Med*, 2014, 6, s. 224–225.
  - 32 **Hay, K. A., et al.**: Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. *Blood*, 2017, 130, s. 2295–2306.
  - 33 **Teachey, D. T., et al.**: Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. *Cancer Discov*, 2016, 6, s. 664–679.
  - 34 **Roselló, S., et al.**: Management of infusion reactions to systemic anti-cancer therapy: ESMO Clinical Practice Guidelines†. *Ann Oncol*, 2017, 28, s. iv100–iv118.
  - 35 **Maakaron, J., et al.**: Procalcitonin as a potential biomarker for differentiating bacterial infectious fevers from cytokine release syndrome. *Blood*, 2018, 132, s. 4216–4216.
  - 36 **Arkader, R., et al.**: Procalcitonin does discriminate between sepsis and systemic inflammatory response syndrome. *Arch Dis Child*, 2006, 91, s. 117–120.
  - 37 **Jain, T. – Litzow, M. R.**: No free rides: management of toxicities of novel immunotherapies in ALL, including financial. *Blood Adv*, 2018, 2, s. 3393–3403.
  - 38 **Klinger, M., et al.**: Pathogenesis-based development of potential mitigation strategies for blinatumomab-associated neurologic events (NEs). *Blood*, 2016, 128, s. 1589–1589.
  - 39 **Jung, S.-H., et al.**: Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome. *Oncotarget*, 2016, 7, s. 55264–55275.
  - 40 **Nisonoff, A. – Woernley, D. L.**: Effect of hydrolysis by papain on the combining sites of an antibody. *Nature*, 1959, 183, s. 1325–1326.
  - 41 **Fudenberg, H. H. – Drews, G. – Nisonoff, A.**: Serologic demonstration of dual specificity of rabbit bivalent hybrid antibody. *J Exp Med*, 1964, 119, s. 151–166.
  - 42 **Dostupné z:** <https://www.nobelprize.org/prizes/medicine/1972/summary/>, T. N. P. in P. or M. 1972. N. org. N. M. A. 2019, vyhledáno 16. 7. 2019.
  - 43 **Kohler, G. – Milstein, C.**: Continuous cultures of fused cells secreting antibody of predefined specificity. *Nature*, 1975, 256, s. 495–497.
  - 44 **Milstein, C. – Cuello, A. C.**: Hybrid hybridomas and their use in immunohistochemistry. *Nature*, 1983, 305, s. 537–540.
  - 45 **Perez, P. – Hoffman, R. W. – Shaw, S., et al.**: Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. *Nature*, 1985, 316, s. 354–356.
  - 46 **Huston, J. S., et al.**: Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in *Escherichia coli*. *Proc Natl Acad Sci U. S. A.*, 1988, 85, s. 5879–5883.
  - 47 **van der Neut Kofschoten, M., et al.**: Anti-inflammatory activity of human IgG<sub>2</sub> antibodies by dynamic Fab arm exchange. *Science*, 2007, 317, s. 1554–1557.
  - 48 **Bargou, R., et al.**: Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. *Science*, 2008, 321, s. 974–977.
  - 49 **Labrijn, A. F. – Janmaat, M. L. – Reichert, J. M., et al.**: Bispecific antibodies: a mechanistic review of the pipeline. *Nat Rev Drug Discov*, 2019.
  - 50 **Köhnke, T. – Krupka, C. – Tischer, J., et al.**: Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab. *J Hematol Oncol*, 2015, 8, s. 111.

## Lymfom z pláštových buněk ve světle nových poznatků

doc. MUDr. Pavel Klener, Ph.D. I. interní klinika hematologie, VFN a 1. LF UK, Praha

- 1 **Hu, Z. – Sun, Y. – Schlette, E. J., et al.**: CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course. *Modern Pathology*, 2018, 31, s. 327–336.
- 2 **Xu, J. – Wang, L. – Li, J., et al.**: SOX11-negative mantle cell lymphoma: clinicopathologic and prognostic features of 75 patients. *Am J Surg Pathology*, 2019, 43, s. 710–716.
- 3 **Martin-García, D. – Navarro, A. – Valdes-Mas, R., et al.**: CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1(-) mantle cell lymphoma. *Blood*, 2019, 133, s. 940–951.
- 4 **Salaverria, I. – Royo, C. – Carvajal-Cuenca, A., et al.**: CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma. *Blood*, 2013, 121, s. 1394–1402.
- 5 **Zhang, J. – Jima, D. – Moffitt, A. B., et al.**: The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells. *Blood*, 2014, 123, s. 2988–2996.
- 6 **Hoster, E. – Dreyling, M. – Klapper, W., et al.**: A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. *Blood*, 2008, 111, s. 558–565.
- 7 **Hoster, E. – Klapper, W. – Hermine, O., et al.**: Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. *J Clin Oncol*, 2014, 32, s. 1338–1346.
- 8 **Hoster, E. – Rosenwald, A. – Berger, F., et al.**: Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European Mantle Cell Lymphoma Network. *J Clin Oncol*, 2016, 34, s. 1386–1394.
- 9 **Hermine, O. – Hoster, E. – Walewski, J., et al.**: Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. *Lancet*, 2016, 388, s. 565–575.
- 10 **Le Gouill, S. – Thieblemont, C. – Oberic, L., et al.**: Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. *New Eng J Med*, 2017, 377, s. 1250–1260.
- 11 **Kluin-Nelemans, H. C. – Hoster, E. – Hermine, O., et al.**: Treatment of older patients with mantle-cell lymphoma. *New Eng J Med*, 2012, 367, s. 520–531.
- 12 **Klener, P. – Fronkova, E. – Belada, D., et al.**: Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma. *Hematol Oncol*, 2018, 36, s. 110–115.
- 13 **Visco, C. – Chiappella, A. – Nassi, L., et al.**: Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. *Lancet Haematol*, 2017, 4, s. e15–e23.
- 14 **Klener, P. – Fronkova, E. – Kalinova, M., et al.**: Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance. *Hematol Oncol*, 2018, 36, s. 773–778.
- 15 **Obr, A. – Prochazka, V. – Papajik, T., et al.**: Maintenance rituximab in newly diagnosed mantle cell lymphoma patients: a real world analysis from the Czech lymphoma study group registry(dagger). *Leukemia & Lymphoma*, 2019, 60, s. 748–755.
- 16 **Klener, P. – Salek, D. – Pytlík, R., et al.**: Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation. *Am J Hematol*, 2019, 94, s. e50–e53.
- 17 **Delfau-Larue, M. H. – Klapper, W. – Berger, F., et al.**: High-dose cytarabine does not overcome the adverse prognostic value of CD-KN2A and TP53 deletions in mantle cell lymphoma. *Blood*, 2015, 126, s. 604–611.
- 18 **Eskelund, C. W. – Dahl, C. – Hansen, J. W., et al.**: TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. *Blood*, 2017, 130, s. 1903–1910.
- 19 **Cheah, C. Y. – George, A. – Gine, E., et al.**: Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. *Ann Oncol*, 2013, 24, s. 2119–2123.
- 20 **Pott, C. – Hoster, E. – Delfau-Larue, M. H., et al.**: Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. *Blood*, 2010, 115, s. 3215–3223.
- 21 **Visco, C. – Tisi, M. C. – Evangelista, A., et al.**: Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death. *Br J Haematol*, 8. 11. 2018, doi: 10.1111/bjh.15643.
- 22 **Dreger, P. – Michallet, M. – Bosman, P., et al.**: Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties. *Bone Marrow Transplant*, 2019, 54, s. 44–52.
- 23 **Rule, S. – Dreyling, M. – Goy, A., et al.**: Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. *Haematologica*, 2019, 104, s. e211–e214.
- 24 **Rule, S. – Dreyling, M. – Goy, A., et al.**: Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies. *Br J Haematol*, 2017, 179, s. 430–438.
- 25 **Wang, M. L. – Rule, S. – Martin, P., et al.**: Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. *New Eng J Med*, 2013, 369, s. 507–516.
- 26 **Dreyling, M. – Jurczak, W. – Jerkeman, M., et al.**: Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell

lymphoma: an international, randomised, open-label, phase 3 study. *Lancet*, 2016, 387, s. 770–778.

27 **Trneny, M. – Lamy, T. – Walewski, J., et al.:** Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial. *Lancet Oncol*, 2016, 17, s. 319–331.

28 **Visco, C. – Finotto, S. – Zambello, R., et al.:** Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell

non-Hodgkin lymphoma in eligible for intensive regimens or autologous transplantation. *J Clin Oncol*, 2013, 31, s. 1442–1449.

29 **Daivids, M. S. – Roberts, A. W. – Seymour, J. F., et al.:** Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. *J Clin Oncol*, 2017, 35, s. 826–833.

30 **Martin, P. – Bartlett, N. L. – Blum, K. A., et al.:** A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma. *Blood*, 2019, 133, s. 1201–1204.

31 **Martin, P. – Maddocks, K. – Leonard, J. P., et al.:** Postbortrutinib outcomes in patients with mantle cell lymphoma. *Blood*, 2016, 127, s. 1559–1563.

32 **Cheah, C. Y. – Chihara, D. – Romaguera, J. E., et al.:** Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. *An Oncol*, 2015, 26, s. 1175–1179.

## Relabující lymfom z pláštových buněk léčený úspěšně ibrutinibem – kazuistika

MUDr. Juraj Ďuraš | prof. MUDr. Roman Hájek, CSc. Klinika hematonekologie, FN Ostrava, Klinika hematonekologie, LF Ostravské univerzity, Ostrava

1 A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. *Blood*, 1997, 89, s. 3909–3918.

2 **Dreyling, M. – Campo, E. – Hermine, O., et al.:** Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*, 2017, 28, s. iv62–71.

3 **Abrahamsson, A. – Albertsson-Lindblad, A. – Brown, P. N., et al.:** Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study. *Blood*, 2014, 124, s. 1288–1295.

4 **Smith, A. – Crouch, S. – Lax, S., et al.:** Lymphoma incidence, survival and prevalence 2004–2014: sub-type analyses from the UK's Haematological Malignancy Research Network. *Br J Cancer*, 2015, 112,

s. 1575–1584.

5 **Le Gouill, S. – Thieblemont, C. – Oberic, L., et al.:** Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. *N Engl J Med*, 2017, 377, s. 1250–1260.

6 **Kluin-Nelemans, H. C. – Hoster, E. – Hermine, O., et al.:** Treatment of older patients with mantle-cell lymphoma. *N Engl J Med*, 2012, 367, s. 520–531.

7 **Trneny, M. – Kleiner, P. – Belada, D., et al.:** The outcome of mantle cell lymphoma patients after treatment failure and prognostic value of secondary Mantle Cell International Prognostic Index (sec MIPI). *Blood*, 2014, 124, s. 4425–4425.

8 **Ponader, S. – Chen, S.-S. – Buggy, J. J., et al.:** The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia

cell survival and tissue homing in vitro and in vivo. *Blood*, 2012, 119, s. 1182–1189.

9 **Cinar, M. – Hamedani, F. – Mo, Z., et al.:** Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by ibrutinib induces apoptosis. *Leuk Res*, 2013, 37, s. 1271–1277.

10 **Rule, S. – Dreyling, M. – Goy, A., et al.:** Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. *Haematologica*, 2019, 104, s. e211–e214.

11 **Wang, M. L. – Blum, K. A. – Martin, P., et al.:** Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. *Blood*, 2015, 126, s. 739–745.

## Ibrutinib v léčbě refrakterního lymfomu z pláštových buněk – kazuistika

MUDr. Heidi Móciková, Ph.D. Interní hematologická klinika FNKV a 3. LF UK, Praha

1 **Owen, C. – Berinstein, N. L. – Christofides, A. – Sehn, L. H.:** Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma. *Curr Oncol*, 2019, 26, s. e233–e240.

2 **Diamond, B. – Kumar, A.:** Mantle cell lymphoma: current and emerging treatment strategies and unanswered questions. *Hematol Oncol Clin North Am*, 2019, 33, s. 613–626.

3 **Tam, C. S. – Anderson, M. A. – Pott, C., et al.:** Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. *N Engl J Med*, 2018,

378, s. 1211–1223.

4 **Dreyling, M. – Jurczak, W. – Jerkeman, M., et al.:** Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle cell lymphoma: an international, randomised, open-label, phase 3 study. *Lancet*, 2016, 387, s. 770–778.

5 **Wang, M. L. – Lee, H. – Chuang, H., et al.:** Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. *Lancet Oncol*, 2016, 17, s. 48–56.

6 **Advani, R. H. – Buggy, J. J. – Sharman, J. P., et al.:** Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. *J Clin Oncol*, 2013, 31, s. 88–94.

7 **Wang, M. L. – Rule, S. – Martin, P., et al.:** Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. *N Engl J Med*, 2013, 369, s. 507–516.

## Použití ibrutinibu jako „bridging“ k alogenní transplantaci krvetvorných buněk od haploidentického dárce a následné terapii reziduální nemoci po transplantaci u pacientky s vysoce nepříznivým průběhem lymfomu z pláštových buněk – kazuistika

MUDr. Veronika Válková, CSc. Ústav hematologie a krevní transfuze, Ústav klinické a experimentální terapie UK, Praha

1 **Eskelund, C. W. – Dahl, C. – Hansen, J. W., et al.:** TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemotherapy. *Blood*, 2017, 126, 130, s. 1903–1910.

2 **Greenwell, I. B. – Staton, A. D., et al.:** Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. *Cancer*, 2018, 124, s. 2306–2315.

3 **Rule, S. – Dreyling, M. – Goy, A., et al.:** Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. *Haematologica*, 2019, 104, s. e211–e214.

4 **Wang, M. – Rule, S. – Zinzani, P. L., et al.:** Acalabrutinib in relapsed

or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. *Lancet*, 2018, 391, s. 659–667.

5 **Robinson, S. P. – Boumendil, A. – Finel, H., et al.:** Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party. *Bone Marrow Transplant*, 2018, 53, s. 617–624.

6 **Lin, R. J. – Ho, C. – Hilden, P. D., et al.:** Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations. *Br J Haematol*, 2019, 184, s. 1006–1010.

7 **Dreger, P. – Michallet, M. – Bosman, P., et al.:** Ibrutinib for bridging to

allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties. *Bone Marrow Transplant*, 2019, 54, s. 44–52.

8 **Dietrich, S. – Dreger, P. – Hermine, O., et al.:** Haploidentical stem cell transplantation for patients with lymphoma: a position statement from the Lymphoma Working Party-European Society for Blood and Marrow Transplantation. *Bone Marrow Transplant*, 31. 5. 2019.

9 **Lysák, D.:** Imunoterapie pomocí CAR-T-lymfocytů. *Onkologie*, 2015, 9, s. 13–18.

## Cílená terapie chronické lymfocytární leukemie

MUDr. Jakub Trizuljak | prof. MUDr. Michael Doubek, Ph.D. Interní hematologická a onkologická klinika, Lékařská fakulta a Fakultní nemocnice Brno, Středoevropský technologický institut (CEITEC) Masarykovy univerzity, Brno

1 **Hallek, M.:** Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. *Am J Hematol*, 2017, 92, s. 946–965.

2 **Byrd, J. C. – Furman, R. R. – Coutre, S. E., et al.:** Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. *N Engl J Med*, 2013, 369, s. 32–42.

3 **Byrd, J. C. – Brown, J. R. – O'Brien, S., et al.:** Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. *N Engl J Med*, 2014, 371, s. 213–223.

4 **O'Brien, S. M. – Byrd, J. C. – Hillmen, P., et al.:** Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. *Am J Hematol*,

2019, 94, s. 554–562.

5 **Burger, J. A. – Keating, M. J. – Wierda, W. G., et al.:** Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukemia: a single-arm, phase 2 study. *Lancet Oncol*, 2014, 15, s. 1090–1099.

6 **Jaglow, S. M. – Jones, J. A. – Nagar, V., et al.:** Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. *Blood*, 2015, 126, s. 842–850.

7 **Sharman, J. – Farber, C. M. – Mahadevan, D., et al.:** Ublituximab (TG-1101), a novel glycoengineered anti-CD20 mAb, in combination with ibrutinib achieves 95% ORR in patients with high-risk relapsed/

refractory CLL. 13<sup>th</sup> International Conference on Malignant Lymphoma (ICML); 2015, Lugano, Švýcarsko.

8 **Niemann, C. U. – Montraveta, A. – Herman, S. E., et al.:** The novel Bruton's tyrosine kinase inhibitor ACP-196 shows in vivo efficacy against human chronic lymphocytic leukemia cells xenografted to the NSG mouse model. Výroční zasedání American Association of Cancer Research, 2014, p. 2624a.

9 **Byrd, J. C. – Harrington, B. – O'Brien, S., et al.:** Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. *N Engl J Med*, 2016, 374, s. 323–332.

10 **Covey, T. – Barf, T. – Gulrajani, M., et al.:** ACP-196: a novel covalent

- Brunon's tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients. Výroční zasedání American Association of Cancer Research, 2015, p. 2596a.
- Fegan, C. – Bagshawe, J. – Salles, G., et al.: The Bruton's tyrosine kinase (BTK) inhibitor ONO-4059: promising single agent activity and well tolerated in patients with high risk chronic lymphocytic leukaemia (CLL). Výroční zasedání American Society of Hematology, 2014, p. 3328a.
  - Brown, J. R. – Harb, W. A. – Hill, B. T., et al.: Phase 1 study of single agent CC-292, a highly selective Bruton's tyrosine kinase (BTK) inhibitor, in relapsed/refractory chronic lymphocytic leukemia (CLL). Výroční zasedání American Society of Hematology, 2013, p. 1630a.
  - Brown, J. R. – Byrd, J. C. – Coutre, S. E., et al.: Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. *Blood*, 2014, 123, s. 3390–3397.
  - Furman, R. R. – Sharman, J. P. – Coutre, S. E., et al.: Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. *N Engl J Med*, 2014, 370, s. 997–1007.
  - Zelenetz, A. D. – Lamanna, N. – Kipps, T. J., et al.: A phase 2 study of idelalisib monotherapy in previously untreated patients  $\geq$  65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). *Blood*, 2014, 124, 1986a.
  - O'Brien, S. – Patel, M. – Kahl, B. S., et al.: Duvelisib (IPI-145), a PI3K- $\delta$  inhibitor, is clinically active in patients with relapsed/refractory chronic lymphocytic leukemia. Výroční zasedání American Society of Hematology, 2014, p. 3334 (San Francisco).
  - Porcu, P. – Flinn, I. – Kahl, B. S., et al.: Clinical activity of duvelisib (IPI-145), a phosphoinositide-3-kinase- $\delta$  inhibitor, in patients previously treated with ibrutinib. Výroční zasedání American Society of Hematology, 2014, p. 3335a.
  - Burris, H. A. – Patel, M. R. – Fenske, T. S., et al.: Clinical activity and safety profile of TGR-1202, a novel once daily PI3K $\delta$  inhibitor, in patients with CLL and B-cell Lymphoma. 13<sup>th</sup> International Conference on Malignant Lymphoma (ICML), 2015, Lugano, Švýcarsko.
  - Burger, J. A. – Chiorazzi, N.: B cell receptor signaling in chronic lymphocytic leukemia. *Trends Immunol*, 2013, 34, s. 592–601.
  - Friedberg, J. W. – Sharman, J. – Sweetenham, J., et al.: Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. *Blood*, 2010, 115, s. 2578–2585.
  - Barr, P. M. – Saylor, G. B. – Spurgeon, S., et al.: Phase 2 trial of GS-9973, a selective syk inhibitor, and idelalisib (idel) in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma. *J Clin Oncol*, 2014, 32, suppl., s. 7059-7059.
  - O'Brien, S. M. – Kantarjian, H. – Thomas, D. A., et al.: Rituximab dose-escalation trial in chronic lymphocytic leukemia. *J Clin Oncol*, 2001, 19, s. 2165–2170.
  - Byrd, J. C. – Murphy, T. – Howard, R. S., et al.: Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. *J Clin Oncol*, 2001, 19, s. 2153–2164.
  - Hallek, M. – Fischer, K. – Fingerle-Rowson, G., et al.: Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. *Lancet*, 2010, 376, s. 1164–1174.
  - Pawluczukowicz, A. W. – Beurskens, F. J. – Beum, P. V., et al.: Binding of submaximal CD19 promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. *J Immunol*, 2009, 183, s. 749–758.
  - Hillmen, P. – Robak, T. – Janssens, A., et al.: Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. *Lancet*, 2015, 385, s. 1873–1883.
  - Doubek, M. – Brychtova, Y. – Panovska, A., et al.: Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study. *Am J Hematol*, 2015, 90, s. 417–421.
  - Goede, V. – Fischer, K. – Busch, R., et al.: Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. *N Engl J Med*, 2014, 370, s. 1101–1110.
  - Goede, V. – Fischer, K. – Engelke, A., et al.: Obinutuzumab as front-line treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. *Leukemia*, 2015, 29, s. 1602–1604.
  - Hillmen, P. – Skotnicki, A. B. – Robak, T., et al.: Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. *J Clin Oncol*, 2007, 25, s. 5616–5623.
  - Pettitt, A. R. – Jackson, R. – Carruthers, S., et al.: Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. *J Clin Oncol*, 2012, 30, s. 1647–1655.
  - Lepretre, S. – Aurran, T. – Mahe, B., et al.: Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. *Blood*, 2012, 119, s. 5104–5110.
  - Byrd, J. C. – Pagel, J. M. – Awan, F. T., et al.: A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 monospecific ADAPTR therapeutic protein in chronic lymphocytic leukemia. *Blood*, 2014, 123, s. 1302–1308.
  - Maddocks, K. J. – Pagel, J. – Byrd, J. C., et al.: Phase 1b Study of otlertuzumab (TRU-016), an anti-CD37 ADAPTR protein, in combination with rituximab in patients with chronic lymphocytic leukemia (CLL). Výroční zasedání American Society of Hematology, 2014, p. 4671a.
  - Roberts, A. W. – Seymour, J. F. – Brown, J. R., et al.: Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. *J Clin Oncol*, 2012, 30, s. 488–496.
  - Souers, A. J. – Levenson, J. D. – Boghaert, E. R., et al.: ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. *Nat Med*, 2013, 19, s. 202–208.
  - Seymour, J. F. – Davids, M. S. – Pagel, J. M., et al.: ABT-199: novel BCL-2 specific inhibitor updated results confirm substantial activity and durable responses in high-risk CLL. Výroční zasedání European Hematology Association, 2014, p. S702 (Milán, Itálie).
  - Jain, N. – Keating, M. – Thompson, P., et al.: Ibrutinib and venetoclax for first-line treatment of CLL. *N Engl J Med*, 2019, 380, s. 2095–2103.
  - Chanani-Khan, A. – Miller, K. C. – Musial, L., et al.: Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. *J Clin Oncol*, 2006, 24, s. 5343–5349.
  - Chen, C. I. – Bergsagel, P. L. – Paul, H., et al.: Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. *J Clin Oncol*, 2011, 29, s. 1175–1181.
  - Chen, C. I. – Paul, H. – Wang, T., et al.: Long-term follow-up of a phase 2 trial of single agent lenalidomide in previously untreated patients with chronic lymphocytic leukaemia. *Br J Haematol*, 2014, 165, s. 731–773.
  - Chanani-Khan, A. – Miller, K. C. – Lawrence, D., et al.: Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. *Cancer*, 2011, 117, s. 2127–2135.
  - Phelps, M. A. – Lin, T. S. – Johnson, A. J., et al.: Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. *Blood*, 2009, 113, s. 2637–2645.
  - Flynn, J. – Jones, J. – Johnson, A. J., et al.: Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia. *Leukemia*, 2015, 29, s. 1524–1529.
  - Davila, M. L. – Bouhassira, D. C. – Park, J. H., et al.: Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies. *Int J Hematol*, 2014, 99, s. 361–371.
  - Porter, D. L. – Hwang, W. T. – Frey, N. V., et al.: Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. *Sci Transl Med*, 2015, 7, 303ra139.
  - McClanahan, F. – Hanna, B. – Miller, S., et al.: PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia. *Blood*, 2015, 126, s. 203–211.
  - Hing, Z. A. – Mantel, R. – Beckwith, K. A., et al.: Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia. *Blood*, 2015, 125, s. 3128–3132.

## Venetoklax – opakované použití u nemocné s prognosticky nepříznivou chronickou lymfocytární leukemií

MUDr. Jana Zuchnická Klinika hematologie Fakultní nemocnice Ostrava

- Hallek, M.: Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. *Am J Hematol*, 2017, 92, s. 946–965.
- Hallek, M. – Cheson, B. D. – Catovsky, D., et al.: iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. *Blood*, 2018, 131, s. 2745–2760.
- Seymour, J. F. – Kipps, T. J. – Eichhorst, B., et al.: MURANO trial establishes feasibility of time-limited venetoclax-rituximab (VenR) combination therapy in relapsed/refractory (R/R) chronic lymphocytic leukemia. *Blood*, 2018, 132, s. 184.
- Mato, A. R. – Tam, C. S.: Disease and patient characteristics, patterns of care, toxicities, and outcomes of chronic lymphocytic leukemia (CLL) patients treated with venetoclax: a multicenter study of 204 patients. *ASH 2017*, abstrakt 4315.
- Anderson, M. A. – Tam, C. – Lew, T. E., et al.: Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. *Blood*, 2017, 129, s. 3362–3370.
- Seymour, J. F. – Ma, S. – Brander, D. M., et al.: Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. *Lancet Oncol*, 2017, 18, s. 230–240.
- Doubek, M. – Špaček, M. – Pospíšilová, Š., et al.: Doporučení pro diagnostiku a léčbu chronické lymfocytární leukemie (CLL) – 2018. *Transfuzie Hematol Dnes*, 2018, 24, s. 208–220.

## Léčba esenciální trombocytémie anagrelidem

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha

- Tefferi, A. – Vannucchi, A. M. – Barbui, T.: Essential thrombocythemia treatment algorithm 2018. *Blood Cancer J*, 2018, 8, s. 2.
- Improved pharmaceutical formulation. Dostupné z: <https://patentscope.wipo.int/search/fr/detail.jsf?sessionid=91087752504B518D650B7130880BB6AE.wapp1nA?docid=WO2016198166&tab=PTDESCRIPTION&maxRec=1000>. 2019, vyhledáno 28. 8. 2019.
- Wang, G. – Franklin, R. – Hong, Y., et al.: Comparison of the biological activities of anagrelide and its major metabolites in hematopoietic cell cultures. *Br J Pharmacol*, 2005, 146, s. 324–332.
- Thiele, J. – Kvasnicka, H. M. – Fuchs, N., et al.: Anagrelide-induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. An immunohistochemical and morphometric study of sequential trephine biopsies. *Haematologica*, 2003, 88, s. 1130–1138.
- Tomer, A.: Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia. *Blood*, 2002, 99, s. 1602–1609.
- Spencer, C. M. – Brogden, R. N.: Anagrelide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of thrombocythaemia. *Drugs*, 1994, 47, s. 809–822.
- Cacciola, R. – Cipolla, A. – Di, F. E., et al.: Treatment of symptomatic patients with essential thrombocythemia: effectiveness of anagrelide. *Am J Hematol*, 2005, 80, s. 81–83.
- Lev, P. R. – Marta, R. F. – Vassallo, P., et al.: Variation of PDGF, TGF beta, and bFGF levels in essential thrombocythemia patients treated with anagrelide. *Am J Hematol*, 2002, 70, s. 85–91.
- Wagstaff, A. J. – Keating, G. M.: Anagrelide: a review of its use in the management of essential thrombocythaemia. *Drugs*, 2006, 66, s. 111–131.
- Harrison, C. N. – Campbell, P. J. – Buck, G., et al.: Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. *N Engl J Med*, 2005, 353, s. 33–45.
- Gisslinger, H. – Gotic, M. – Holowiecki, J., et al.: Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. *Blood*, 2013, 121, s. 1720–1728.
- Ge, X. – Yang, L. – Jin, J., et al.: Efficacy and safety of anagrelide in treatment of essential thrombocythemia: multicenter, randomized controlled clinical trial. *Zhonghua Xue Ye Xue Za Zhi*, 2015, 36, s. 547–552.
- Kanakura, Y. – Shirasugi, Y. – Yamaguchi, H., et al.: A phase 3b, multicenter, open-label extension study of the long-term safety of anagrelide in Japanese adults with essential thrombocythemia. *Int J Hematol*, 2018, 108, s. 491–498.

# Buněčná terapie u akutních leukemií

MUDr. Jan Vydra Ústav hematologie a krevní transfuze, Praha

- 1 Gale, R. P., et al.: Identical-twin bone marrow transplants for leukemia. *Ann Intern Med*, 1994, 120, s. 646–652.
- 2 Orti, G., – Barba, P. – Fox, L., et al.: Donor lymphocyte infusions in AML and MDS: Enhancing the graft-versus-leukemia effect. *Exp Hematol*, 2017, 48, s. 1–11.
- 3 Maude, S. L., et al.: Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. *N Engl J Med*, 2018, 378, s. 439–448.
- 4 Johnson, J. K. – Miller, J. S.: Current strategies exploiting NK-cell therapy to treat haematologic malignancies. *Int J Immunogenet*, 2018, 5, s. 237–246.
- 5 Weisdorf, D., et al.: T cell-depleted partial matched unrelated donor transplant for advanced myeloid malignancy: KIR ligand mismatch and outcome. *Biol Blood Marrow Transplant*, 2012, 18, s. 937–943.
- 6 Ruggeri, L., et al.: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. *Science*, 2002, 295, s. 2097–2100.
- 7 Ciurea, S. O., et al.: Phase 1 clinical trial using mbl21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation. *Blood*, 2017, s. 1857–1868.
- 8 Choi, I., et al.: Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study. *Biol Blood Marrow Transplant*, 2014, s. 696–704.
- 9 Sahin, U. – Dalva, K. – Gungor, F., et al.: Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation. *Ann Hematol*, 2018, s. 1027–1039.
- 10 Miller, J. S., et al.: Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. *Blood*, 2005, s. 3051–3057.
- 11 Curti, A., et al.: Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. *Blood*, 2011, s. 3273–3279.

# Diagnostika a terapie sekundárních protilátkových imunodeficiencí u hematoonkologických pacientů z pohledu imunologa

MUDr. Tomáš Milota Ústav imunologie 2. LF UK a FN v Motole, Praha

- 1 Česká onkologická společnost ČLS JEP, www.linkos.cz.
- 2 LeBien, T. W. – Tedder, T. F.: B lymphocytes: how they develop and function. *Blood*, 2008, 112, s. 1570–1580.
- 3 Warnatz, K. – Schlesier, M.: Flowcytometric phenotyping of common variable immunodeficiency. *Cytometry B Clin Cytom*, 2008, 74, s. 261–271.
- 4 Roth, D. B.: V(D)J Recombination: mechanism, errors, and fidelity. *Microbiol Spectr*, 2014, 2.
- 5 Shaffer, A. L., 3<sup>rd</sup> – Young, R. M. – Staudt, L. M.: Pathogenesis of human B cell lymphomas. *Annu Rev Immunol*, 2012, 30, s. 565–610.
- 6 Marshall, M. J. E. – Stopforth, R. J. – Cragg, M. S.: Therapeutic antibodies: what have we learnt from targeting CD20 and where are we going? *Front Immunol*, 2017, 8, s. 1245.
- 7 Patel, S. Y. – Carbone, J. – Jolles, S.: The expanding field of secondary antibody deficiency: causes, diagnosis, and management. *Front Immunol*, 2019, 10, s. 33.
- 8 Mondello, P., et al.: 90 Y-ibritumomab tiuxetan: a nearly forgotten opportunity. *Oncotarget*, 2016, 7, s. 7597–7609.
- 9 Shah, N. N., et al.: Multi targeted CAR-T cell therapies for B-cell malignancies. *Front Oncol*, 2019, 9, s. 146.
- 10 Bonavida, B.: Postulated mechanisms of resistance of B-cell non-Hodgkin lymphoma to rituximab treatment regimens: strategies to overcome resistance. *Semin Oncol*, 2014, 41, s. 667–677.
- 11 Barmettler, S., et al.: Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. *JAMA Netw Open*, 2018, 1, s. e184169.
- 12 Worch, J. – Makarova, O. – Burkhardt, B.: Immunrestitution and infectious complications after rituximab treatment in children and adolescents: what do we know and what can we learn from adults? *Cancers (Basel)*, 2015, 7, s. 305–328.
- 13 Duraisingham, S. S., et al.: Secondary antibody deficiency. *Expert Rev Clin Immunol*, 2014, 10, s. 583–591.
- 14 Srivastava, S. – Wood, P.: Secondary antibody deficiency – causes and approach to diagnosis. *Clin Med (Lond)*, 2016, 16, s. 571–576.
- 15 Compagno, N., et al.: Immunoglobulin replacement therapy in secondary hypogammaglobulinemia. *Front Immunol*, 2014, 5, s. 626.
- 16 Agostini, C., et al.: Prophylactic immunoglobulin therapy in secondary immune deficiency – an expert opinion. *Expert Rev Clin Immunol*, 2016, 12, s. 921–926.
- 17 Dhalla, F. – Misbah, S. A.: Secondary antibody deficiencies. *Curr Opin Allergy Clin Immunol*, 2015, 15, s. 505–513.